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ABSTRACT

Signaling through the Epidermal Growth Factor Receptor (EGFR) plays an
important role in both physiological and cancer-related processes. In this work,
single-molecule microscopy measurements and computational modeling were
closely integrated to better understand the mechanisms that regulate EGFR
signaling. Technical improvements were made over the previously described
Single-Molecule Pull-down (SiMPull) assay to facilitate direct detection of the
phosphorylation state of thousands of individual receptors, and thereby estimate
both the fraction of receptors phosphorylated at specific tyrosine residues and
the frequency of multisite phosphorylation. These improvements enabled the first
direct detection of multisite phosphorylation on full-length Epidermal Growth
Factor Receptor (EGFR), and revealed that the extent of phosphorylation varied
by tyrosine residue (biased phosphorylation). To help in understanding the
underlying processes giving rise to these observations, a rule-based model for
EGFR

signaling

was

developed.

The

model

suggested

that

biased

phosphorylation could be explained by variations in adaptor protein abundances.
iv

This prediction arises from the structure of the model, in which a phospho-site
that is bound by an adaptor protein is sterically protected from the action of
phosphatases. Testing model predictions confirmed that overexpression of the
adaptor protein Grb2 leads to phosphorylation levels enhanced specifically at a
site where this protein binds. Finally, this model was extended to explore the
possible mechanisms leading to differential signaling induced by EGFR ligands.
Model results suggest that ligand-dependent differences in dimer lifetimes lead to
differential multisite phosphorylation and ubiquitination, which in turn could
influence signaling kinetics and cellular outcomes.
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Chapter 1 : Introduction

1.1 Overview
Complex multicellular organisms, such as the human body, depend on the
ability of its individual cells to respond in a precise and coordinated fashion to
stimuli coming either from other cells or from the surrounding environment. The
transmission of stimuli from the exterior of the cell to its interior occurs through a
process called signal transduction or cell signaling. For example, binding of
ligands to membrane receptors starts a cascade of molecular events, such as
protein phosphorylation and interactions, that propagate the signal to the nucleus
and eventually lead to cellular responses. Even though the overall picture of
many signal transduction pathways is known, many critical details remain poorly
understood. One such detail is the heterogeneity in the activation states of
molecules participating in signal transduction, a feature that cannot be provided
by commonly used ensemble techniques. To address this issue, a singlemolecule microscopy technique was improved, allowing for access to this kind of
information. The work presented here focuses in the study of activation states of
the Epidermal Growth Factor Receptor (EGFR). Additionally, computational
models were used to help understanding the underlying processes giving rise to
the observed distribution of activated states.
In this introduction, some of the features of the EGFR signaling pathway
are described, including signal initiation, transmission and regulation. Next, the
advantages and limitations of ensemble and single-molecule techniques are
1

discussed. Then, some of the previous work relating to modeling of EGFR
signaling and the current advances in modeling techniques is described. The
final part of this section contains the central hypothesis for this work and a
summary of the results obtained.

1.2 Signaling through the Epidermal Growth Factor Receptor
1.2.1 Introduction
The Epidermal Growth Factor Receptor (EGFR) belongs to the
EGFR/erbB family of Receptor Tyrosine Kinases, which consists of four
members: EGFR (erbB1, HER1), HER2 (erbB2), HER3 (erbB3), and HER4
(erbB4). In general, these proteins are single-pass transmembrane proteins with
an extracellular ligand binding domain and a cytoplasmic tail containing a
tyrosine kinase domain (Figure 1.1) (Lemmon and Schlessinger, 2010; Yarden
and Sliwkowski, 2001). As exceptions, HER2 has no known ligand, and HER3
kinase activity is dependent on initial activation by HER2 (Steinkamp et al.,
2014). Ligand binding to these transmembrane proteins leads to conformational
changes, receptor homo- and hetero-dimerization, kinase activation and the
transphosphorylation of multiple cytoplasmic tail tyrosines (Schlessinger, 2002).
These phosphotyrosines in turn provide sites for the recruitment and activation of
cytoplasmic proteins, initiating signaling cascades that control numerous cellular
processes such as gene expression, cell migration and cell division.
Dysregulation of EGFR signaling, commonly caused by receptor overexpression

2

and/or mutation, has been associated with development and progression of
cancer.

Figure 1.1. Ligand-induced EGFR dimerization and activation. EGFR ligands
include EGF, TGF-α and epiregulin.
In recent years there has been growing evidence that suggests that EGFR
activation may not only form dimers, but also tetramers and higher-order
oligomers (Kozer et al., 2014, 2013a). Considering that most of the available
information about EGFR activation relates to receptor dimerization, this study
focuses on this form of signal initiation.
1.2.2 Recruitment of adaptor proteins to activated receptors
Activated EGFR is capable of recruiting a variety of adaptor proteins that
have different roles in signal transduction and regulation of cellular outcomes. A
few examples of these proteins and the specific sites to which they bind is
displayed in Figure 1.2a. The first part of this dissertation focuses on the study of
3

the phosphorylation of tyrosines 1068 and 1173, and the recruitment of Grb2 and
Shc1 to these sites (Figure 1.2b). Proteins recruited to the receptor can be
phosphorylated either by EGFR or by other kinases such as Src. Grb2 can bind
to phosphorylated Shc1, and therefore be recruited to the receptor indirectly
through Shc1 (Batzer et al., 1994). Even though both Y1068 and Y1173 can
recruit Grb2, either directly or indirectly, and lead to activation of MAPK pathway,
these sites have distinct additional roles in signaling. For example, pY1173 can
also recruit and activate PLC-γ and calcium signaling, or recruit the phosphatase
Shp1, as shown in Figure 1.2a. On the other hand, pY1068 has been shown to
be essential for efficient recruitment of the E-3 ubiquitin ligase Cbl, which
ubiquitinates EGFR and mediates its downregulation (Sigismund et al., 2013).
The interaction of Grb2 and Cbl, and the proximity of their recruitment
sites, seems to give rise to a cooperative behavior in which the stability of the
Cbl-Grb2 complex is higher than that of the individual proteins (Figure 1.2c).
Chapter 5 of this dissertation focuses on the computational modeling of this
interaction, and how differences in stability of receptor dimers induced by distinct
EGFR ligands could regulate this interaction, and eventually lead to different
signaling behavior.

4

Figure 1.2. Recruitment capacity of activated EGFR. Description. (a)
Representation of some of the adaptor proteins recruited to activated EGFR.
Based on (Olayioye et al., 2000). (b) Sites and interactions considered for first
part of this dissertation. (c) Sites and interactions considered in Chapter 5. Cbl
and Grb2 can interact.

1.2.3 Protein tyrosine phosphatases (PTPs) and EGFR signaling
Phosphorylation levels are the net result of protein phosphorylation and
dephosphorylation. A phosphate group can be added at the amino acid residues
tyrosine, serine or threonine. In the case of phosphorylated tyrosines, in which
this dissertation focuses, protein tyrosine phosphatases (PTPs) are the
responsible for removing the phosphate groups from this amino acid. PTPs play
a very important role in regulating EGFR signaling, both before and during ligand
stimulation. For example, in many cell types phosphorylation of receptor tyrosine
kinases (RTKs) is undetectable in the absence of ligand, but inhibition of PTPs
5

results in important levels of receptor phosphorylation (Jallal et al., 1992; Tarcic
et al., 2009). This basal phosphorylation, which is thought to originate from short
interactions between unliganded receptors, is suppressed by constantly active
phosphatases. Phosphatase activity can be regulated both in time and space.
For example, while DEP-1 causes receptor dephosphorylation at the membrane,
PTP1B seems to mainly locate and cause EGFR dephosphorylation at
endosomes (Tarcic et al., 2009; Eden et al., 2010; Yudushkin et al., 2007). Even
though most PTPs are known to downregulate EGFR signaling, there are
examples where a phosphatase can enhance downstream signaling (Yao et al.,
2017).
The timescale of phosphorylation and dephosphorylation events was
recently informed by a combination of experimental and computational modeling
techniques (Kleiman et al., 2011). Kleiman et al. showed that activated EGFR is
quickly dephosphorylated after a few seconds of adding a fast-binding kinase
inhibitor. Their modeling results suggest that receptors can go through hundreds
of phosphorylation/dephosphorylation cycles in the order of a few minutes. Each
of these events require energy in the form of ATP. A fast dynamic interplay
between these two processes is essential for allowing the cell to respond in a
prompt manner to external stimuli and to prevent spurious and excessive
signaling.
1.2.4 Regulation of EGFR signaling by endocytosis
EGFR signaling can be regulated both in time and space. After activation,
receptors at the plasma membrane are internalized into endocytic vesicles.
6

Recent studies suggest that receptors at endosomes cannot activate MAPK
pathway, the reason being that Ras, a protein required for MAPK activation, is
mainly located at the plasma membrane and not in endosomes (Pinilla-Macua et
al., 2016). The fate of internalized receptors is regulated by a complex network of
proteins, including components of the ESCRT (endosomal sorting complexes
required for transport) machinery and members of the Rab GTPase family
(Sorkin and Goh, 2009; Schwartz et al., 2007). Depending on different factors,
receptors can be recycled back to the plasma membrane, where they can
continue signaling, or they can be targeted for lysosomal degradation, causing
signal downregulation. One of the main factors regulating the fate of EGFR is
receptor ubiquitination, which in the case of EGFR is mediated by the E3ubiquitin ligase Cbl (Levkowitz et al., 1999). Receptor fate is determined by the
levels and/or type of ubiquitination, which are recognized by Ubiquitin-interacting
motifs (UIMs) present in proteins involved in receptor sorting (Raiborg and
Stenmark, 2009; Huang et al., 2013). The level of ubiquitination and receptor fate
seems to be dependent on ligand type and dose (Roepstorff et al., 2009;
Sigismund et al., 2013). A more in depth discussion about the literature relating
to ligand type- and dose-dependent regulation of endocytosis and signaling is
presented in Chapter 5.

1.3 Comparison between ensemble and single-molecule techniques
There are two broad types of techniques that can be used to study protein
interactions and PTMs (post-translational modifications): ensemble and single7

molecule techniques. In ensemble techniques, the average state of a (generally
large) group of molecules is measured. Examples of this type of techniques
include Western blot and ELISA (enzyme-linked immunosorbent assay), which
measure the relative level of protein interaction- or PTM-state. Single-molecule
techniques on the other hand are able to distinguish the state of individual
molecules. Single-molecule microscopy and atomic force microscopy represent
two of the most used techniques in this category.
Both ensemble and single-molecule techniques have their advantages
and limitations, therefore choice of method depends on different factors such as
considering the level of information that wants to be obtained and the availability
of resources, to name a few. In terms of practicality and cost, ensemble
techniques generally trump. Single-molecule assays generally require costly
equipment and high-level of expertise. Nevertheless, they often provide
information otherwise inaccessible. There are many examples of the power of
single-molecule level measurements to reveal mechanistic details that could not
be studied using ensemble techniques (Oh et al., 2012; Low-Nam et al., 2011;
Munsky et al., 2012; Andrews et al., 2008). Recently, Jain et al. developed a
technique called Single-Molecule Pull-down (SiMPull), which allows to assess the
composition of individual molecular complexes (Jain et al., 2011). Later in this
work, a series of modifications to this technique are described. These
modifications allowed for the quantification of phosphorylation states from
thousands of individual membrane receptors.

8

1.4 Computational modeling of EGFR signaling
The vast amount of experimental data available about EGFR activation
and its downstream signaling events has made it a perfect system for
mathematical and computational studies (Kholodenko et al., 1999; Blinov et al.,
2006; Shankaran et al., 2012). In spite of this body of knowledge, many of the
mechanisms involved in EGFR activation and its regulation are not completely
understood. Modeling of EGFR signaling was generally performed using a series
of simplifications. For example, even though it is known that different
phosphorylated residues in EGFR recruit specific adaptor proteins and have
different functions, these different sites were generally represented as a single
one, for which multiple adaptor would compete for (Figure 1.3a). These
simplifications were in most cases justified, not using them could easily result in
the need of defining hundreds of ordinary differential equations, a process that
would be error-prone and time-consuming. The relatively recent development of
tools that allow for rule-based modeling of biochemical networks has made
possible modeling of signaling systems without the need of employing the
aforementioned simplifications (Faeder et al., 2009; Smith et al., 2012).
In this type of modeling, the user define rules containing only the protein
components that are relevant for the reaction to happen, and the open source
software does the work of creating a reaction for every possible species that is
able to participate in the reaction. In the example presented in Figure 1.3, the
user only needs to define 18 rules total, and the software generates ordinary
differential equations (ODEs) for the 729 possible different species. In this work,
9

this powerful computational technique was used to include site-specific
information about EGFR phosphorylation and recruitment of adaptor proteins.

Figure 1.3. Comparison of traditional vs rule-based modeling approaches. (a)
Traditional models generally lump sites together to prevent the need to define a
high

number

representation

of

ordinary differential
of

rule-based

equations

model

(ODEs).

considering

(b)

Simplified

phosphorylation,

dephosphorylation and reversible adaptor protein binding to six tyrosine residues.
The three possible states for each site are unphosphorylated, phosphorylatedfree, or phosphorylated-occupied (by adaptor protein).

1.5 Hypothesis
My central hypothesis is that upon EGFR activation there are subsets of
receptors having distinct phosphorylation patterns and therefore playing different
10

roles in signal propagation. To test this hypothesis, a series of improvements
were made to the SiMPull technique, allowing the analysis of phosphorylation
states from thousands of receptors. Since phosphorylation kinetics is the result of
a variety of molecular processes, computational modeling was used to aid in the
quest to understand how the interrelation between these events give rise to the
observed behavior.

1.6 Summary of Results
Chapter 2 provides a detailed description of the improvements made to
the SiMPull technique for quantification of receptor multisite phosphorylation.
Results show that only a subpopulation of EGFR become phosphorylated under
what is considered maximal activation conditions and that the extent of
phosphorylation varies by tyrosine residue. Three-color imaging of EGFR-GFP
with antibodies directed to two distinct phospho-sites revealed the presence of a
subset of receptors with simultaneous phosphorylation at the two sites probed.
Chapter 3 describes the development of a rule-based model for the initial
steps of EGFR signaling. Particularly, it considers ligand-induced receptor
activation and the recruitment of the adaptor proteins Grb2 and Shc1 to
phosphorylated tyrosines 1068 and 1173 in EGFR, respectively. In Chapter 4,
the model was fine-tuned with experimental data obtained with the improved
SiMPull technique. Experimental testing of model predictions confirmed that
adaptor proteins are able to protect the sites to which they bind from
dephosphorylation, and therefore modulate the phosphorylation patterns
11

observed in vivo. Chapter 5 describes an extended model developed to help
explain differential signaling induced by EGFR ligands.

The model provides

testable predictions to help dissect the roles of dimer lifetimes and ubiquitination
in this differential signaling. Finally, Chapter 6 provides a brief discussion about
the implications that these results have in the understanding of signaling
pathways, and some of the possible future directions.

12

Chapter 2 : Single Molecule Pull-down for Quantification of
Membrane Receptor Multisite Phosphorylation

Emanuel Salazar-Cavazos1,2, Keith A Lidke2,3, Diane S. Lidke1,2
1Department

of Pathology, 2Comprehensive Cancer Center and 3Department of

Physics & Astronomy, University of New Mexico, Albuquerque, NM 87131
2.1 Introduction
The ability of a cell to respond rapidly and specifically to changes in the
surrounding environment is controlled by protein-protein interactions at the
plasma membrane and along the signaling cascade. While much is known about
the biochemical events that govern signaling pathways, this information has
mostly been derived from population-based measurements that typically average
over millions of cells and/or proteins. However, there is growing evidence that the
heterogeneity of the system contributes to how cellular information is processed
(Lahav et al., 2004; Feinerman et al., 2008; Coba et al., 2009; Spencer et al.,
2009). To better understand the role of protein phosphorylation heterogeneity in
directing signaling outcomes, the single molecule pull down (SiMPull) assay was
adapted to identify the phosphorylation state of individual receptors.
SiMPull is a powerful technique that allows for interrogation of
macromolecular complexes at the individual protein level.

Jain et al. first

demonstrated the ability of this technique to capture macromolecular complexes
(Jain et al., 2011).

SiMPull samples are prepared in a manner similar to

IP/Western Blot protocols, but the sample is interrogated using single molecule
13

microscopy. Briefly, cells are lysed and the protein of interest is captured by
antibodies bound to the coverglass. If the proteins are fluorescently tagged,
either by fluorescent proteins or subsequent antibody labeling, their presence will
be quantified by single molecule imaging (Figure 2.1A).
Here, a modification of SiMPull for the study of phosphorylation patterns of
transmembrane receptors is described. Traditionally, protein phosphorylation has
been measured using ensemble techniques, such as Western Blot analysis or
flow cytometry, which provide information on the relative changes of a protein
phosphorylation amount.

However, these techniques cannot determine the

fractions of proteins in a specific phosphorylation state, much less identify when
an individual protein contains multiple sites of phosphorylation.

While mass

spectrometry has the potential to detect multisite phosphorylation, the residues of
interest must be found in the same small peptide that is generated by enzymatic
digestion (typically 7-35 amino acids) or the protein of interest must be small
(Swaney et al., 2010; Curran et al., 2015; Brunner et al., 2015). Therefore, new
techniques are needed to better understand the phosphorylation status of
individual proteins. Recently, Kim et al. used a modified SiMPull approach,
termed SiMBlot, to pull-down surface biotinylated proteins and identify
phosphorylation using denaturing conditions and phosphorylation-specific
antibody labeling (Kim et al., 2016). Our approach differs in several significant
ways from SiMBlot and provides important improvements over previous protocols
(Jain et al., 2012; Kim et al., 2016), including the reduction of autofluorescence in
the green spectral channel and a simplified imaging chamber that accommodates

14

higher sample number with lower sample volume. Results demonstrate the
importance of optimizing antibody labeling and fixation conditions. To quantify
receptor phosphorylation, two- and three-color imaging were used to identify
individual proteins and their corresponding phosphorylation status. Corrections
to account for membrane receptor surface expression and steric hindrance in the
case of dual antibody labeling are described.
This method was applied to the study of the classical Epidermal Growth
Factor Receptor (EGFR). EGFR has 20 tyrosines in its cytoplasmic tail, at least
12 of which are known to recruit specific adaptor proteins (Schulze et al., 2005).
The potential for multisite phosphorylation provides a mechanism through which
the cell might differentially respond to extracellular cues, depending on the extent
and combination of receptor phosphorylation (Gibson et al., 2000; Salazar and
Höfer, 2009; Coba et al., 2009; Lau et al., 2011). Results showed that only a
subpopulation of EGFR become phosphorylated under what is considered
maximal activation conditions and that the extent of phosphorylation varies by
tyrosine residue. Multiplex imaging of the GFP-tagged receptors and antibodies
directed to two distinct phosphotyrosines revealed that multisite phosphorylation
frequently occurs. The extent of phosphorylation at individual tyrosines along
with the existence of multisite phosphorylation has implications for how EGFR
translates extracellular cues into downstream signaling outcomes.

15

Figure 2.1. SiMPull to quantify protein phosphorylation. (A) Illustration depicting
overall principle for assessing phosphorylation at the single molecule level using
GFP-tagged EGFR (EGFR-GFP) as an example. (B) Representative images
showing raw data (top) and blob-reconstructed localized molecules (bottom).
CHO-EGFR-GFP cells were stimulated for 5 min with 25 nM EGF at 37°C before
lysis for SiMPull. Raw images are brightness and contrast enhanced for
visualization. The EGFR-GFP fits were filtered based on their fit to the
16

microscope point spread function and the GFP-channel used as a mask to create
the

overlay.

The

number in

the

bottom

right

image

represents

the

phosphorylation percentage estimated for this field of view. (C) Hydrophobic
array for preparation of SiMPull samples.

2.2 Results
2.2.1 Visualization of individual protein phosphorylation status by SiMPull
Phosphorylation of EGFR was assayed at the single molecule level using
the SiMPull concept depicted in Figure 2.1A, where the GFP-tagged receptors
from cell lysates are immunoprecipitated by antibodies bound to the coverglass
and subsequently labeled with fluorescently-tagged antibodies detecting
phosphorylated tyrosines (anti-PY).

Figure 2.1B shows the capture of single

EGFR-GFP from cell lysate on the coverglass surface and the corresponding
labeling of phosphorylated EGFR using a pan-phosphotyrosine antibody
conjugated to Alexa Fluor 647 (anti-PY AF647; PY99 antibody). Individual
molecules are identified in each image (Figure 2.1B). Images are then overlaid
to identify phosphorylated receptors. Colocalization of receptor and PY
localizations provide an initial estimate of the fraction of phosphorylated
receptors (Figure 2.1B). Optimization of the experimental process and image
analysis, including reduction in autofluorescence, corrections for the level of
receptor surface expression and the appropriate antibody labeling conditions, are
described in the following sections.
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2.2.2 Simplified sample chamber increases throughput and reduces sample
volume
Jain et al. originally described the use of a fluidic chamber for imaging that
consisted of 4-6 channels generated between a coverglass and microscope slide
using epoxy (Jain et al., 2012).

While these types of flow chambers are

straightforward to produce, the protocol is time consuming (30-60 min) and larger
volumes (~70 µL) are required to fill each channel. To overcome these
limitations, a hydrophobic barrier pen was used to create an array of isolated
sample regions on a coverglass (Figure 2.1C). Rectangular (24x60mm, #1.5)
coverglasses are treated as described and an array of up to 20 squares can be
drawn with the hydrophobic ink pen in a matter of minutes. As little as 10 µL of
sample is needed to fill each region, which is seven times less than for the
original flow channels. This is particularly useful considering the high cost of
fluorescently labeled antibodies and that for some applications sample availability
may be limited. Time for sample preparation is also reduced as washing and
labeling steps are simplified without the need for flowing of buffers through
channels.

2.2.3 Quenching with NaBH4 reduces background autofluorescence
It has been previously noted that autofluorescent background is detected
in the spectral region corresponding to green emitting fluorophores (Jain et al.,
2012). Autofluorescent puncta were also observed in the green spectral channel
(503-548 nm), which were identified as single GFP molecules in the absence of
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cell lysate. Since the experimental approach used relies on GFP to identify the
location of EGFR on the coverglass, it was important to reduce this background
to avoid over-counting of receptors. Incubating the PEG-coated coverglass with
Sodium Borohydride (10 mg/mL NaBH4 for 4 min) was found to significantly
reduce the number of background fluorescent molecules (Figure 2.2). Despite
the improvement in background signal, background measurements were
routinely acquired for each coverglass preparation to enable background
correction for each experiment (see Methods for details).

Figure 2.2. Reduction of autofluorescence with Sodium Borohydride (NaBH4).
(A) Raw images and blob-reconstructions from a typical field of view of a
PEG/PEG-biotin functionalized surface without (left) and with (right) NaBH4treatment. (B) Quantification of the average number of false-positive localizations
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per field of view in surfaces with or without treatment with NaBH 4. For each
condition N > 12 fields of view were analyzed. Error bars represent mean +/S.E.M.

2.2.4 Antibody optimization is required for accurate phosphotyrosine
detection
Since antibodies are used to quantify protein phosphorylation, it is critical
to optimize the antibody labeling protocol. Figure 2.3 presents the results from
optimization of anti-EGFR-pY1068. In these experiments, EGF stimulated cells
were co-treated with a phosphatase inhibitor (pervanadate, PV) to increase the
amount of receptor phosphorylation. Incubation of EGFR-pY1068 on ice for 60
minutes was needed to ensure maximal labeling (Figure 2.3A). Importantly,
results show that over time the antibody dissociates from EGFR, with ~37%
reduction after 1 hr at room temperature (Figure 2.3B, no fixative). Complete
imaging of the sample array can take up to 1 hr, therefore, loss of antibody over
this period would lead to an underestimate of receptor phosphorylation for
samples imaged later in time. Multiple fixation protocols to minimize antibody
unbinding

were

tested.

Results

show

that

fixation

with

4%

Paraformaldehyde/0.1% Glutaraldehyde (PFA/GA) for 10 min stabilized the
antibody levels for at least 1 hr (Figure 2.3B, PFA/GA).
To ensure that saturating levels of antibody are used, concentration
curves for each antibody were generated, using the PFA/GA fixation for optimal
results. The example in Figure 2.3C shows the titration curve for anti-EGFR20

pY1068, which saturates at ~20 g/mL. Consequently, 20 g/mL were used for
all experiments.

Binding affinity will vary for each antibody and fluorescent-

conjugation may also alter antibody affinity. Therefore, it is necessary to perform
a binding curve for each antibody and for each new antibody conjugation.
Another important consideration is the specificity of the antibody for its binding
site. Kim et al demonstrated an elegant way to determine specificity by using
purified proteins with individual tyrosines mutated to alanine. The same EGFRpY1068 and EGFR-pY1173 antibodies that they found to have high specificity
from their in vitro measurements are used in this work (Kim et al., 2016).

Figure 2.3. Optimization of antibody labeling for accurate quantification of
receptor phosphorylation. CHO-EGFR-GFP cells were pre-treated with 1 mM
PV for 15 min and stimulated with 50 nM EGF+1mM PV for 5 min at 37°C to
enhance receptor phosphorylation and interrogated for anti-EGFR-pY106821

CF555 labeling. (A) Antibody labeling with anti-pY1068 requires 60 min to reach
maximal labeling. A 20 g/mL antibody concentration was used. Number of
receptors analyzed per condition, N>3400. (B) Addition of PFA/GA post-fixation
prevents loss of antibody over time. N>2700 per condition. (C) Increase in
labeling as a function of antibody dose. EGFR-pY1068-CF555 saturates at ~20
g/mL. Antibody was incubated for 1 hour on ice and post-fixed with PFA/GA.
Resting cells were used as a control for non-specific labeling. N>1700 per data
point. Error bars are standard error of measured phosphorylation percentages.

2.2.5 Correction is required to account for non-surface localized receptors
At any point in time, a fraction of membrane receptors is trafficking
through intracellular compartments. These internal receptors are not accessible
during addition of extracellular ligand, but will be captured by the antibody during
SiMPull sample preparation and result in an underestimate of receptor
phosphorylation. In CHO-EGFR-GFP cells, a fraction of the receptors are located
in intracellular compartments (Figure 2.4A, left). To determine the fraction of
EGFR accessible to ligand, all surface proteins on the CHO-EGFR-GFP cells
were labeled with membrane-impermeable AF647-NHS Ester (Figure 2.4A, right)
and used SiMPull to visualize the amount of EGFR-GFP colocalized with AF647.
By increasing the concentration of AF647-NHS until saturation is achieved, it was
estimated that ~65% of the receptors are located at the plasma membrane
(Figure 2.4B). With this information, measurements were corrected to account
for only those receptors available to bind ligand. After correction, ~14% of the
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receptors are phosphorylated at Y1068 after 1 min stimulation with 50 nM EGF
(Figure 2.4C). While surface labeling of receptors with AF647-NHS ester allows
for identification of surface proteins, this modification reduced EGF binding (data
not shown). Therefore, pre-labeling of receptors was not used for the study of
EGFR activation.
To validate the correction method, the phosphorylation levels of receptors
were measured in CHO cells expressing ACP-tagged EGFR. EGFR localized at
the plasma membrane was directly labeled using membrane-impermeable CoAAtto488 as describe previously (Valley et al., 2015; Ziomkiewicz et al., 2013).
Cells were then exposed to EGF and probed for EGFR phosphorylation with
SiMPull, this time using Atto488 as the marker for plasma membrane EGFR. The
percent of phosphorylated EGFR was similar when comparing the membranelocalized ACP-EGFR and the membrane-corrected EGFR-GFP samples (Figure
2.4C). Therefore, the effects of EGF binding to EGFR on the plasma membrane
can be accurately determined from whole cell lysates using the correction, which
was applied for the remainder of the results.
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Figure 2.4. Correction for cellular distribution of receptors. (A) Confocal images
showing typical distribution of EGFR-GFP in CHO cells (left) and the labeling of
surface proteins achieved with the AF647-NHS ester (right). (B) Cells were
incubated with increasing concentrations of AF647-NHS and assayed by SiMPull
to determine the percentage of EGFR-GFP molecules labeled with AF647.
Number of receptors analyzed per data point, 850 < N < 1550. (C) Percentage of
pY1068+ receptors estimated for EGFR-GFP before and after correcting for
surface expression. The corrected phosphorylation percentage for EGFR-GFP
corresponds to the value measured for ACP-EGFR, which only includes plasma
24

membrane localized receptors. N>2400 for each EGFR type.

Error bars are

standard error of measured phosphorylation percentages.

2.2.6 Extent of phosphorylation varies by tyrosine residue
SiMPull was used to characterize the kinetics and dose response of EGFR
activation. The multi-well hydrophobic array (Figure 2.1C) made it possible to
efficiently examine a full dose response or time course of activation in a single
imaging session.

Total EGFR tyrosine phosphorylation (PY) and the

phosphorylation patterns for two specific tyrosine sites (Y1068 and Y1173) were
quantified.

Cells simulated for 5 min (Figure 2.5A) with increasing

concentrations of EGF showed the expected increase in total phosphorylation
with ligand dose (Figure 2.5A, PY, blue bars). This fraction reached 64% with 50
nM EGF, a dose that is considered saturating. While both specific tyrosines show
less phosphorylation than total PY, the fraction of EGFR with phosphorylation at
Y1173 was consistently higher than at Y1068 (Figure 2.5A). The kinetics of
phosphorylation between PY, pY1068 and pY1173 are similar (Figure 2.5B).
These results indicate several important outcomes. First, phosphorylation
detection by SiMPull is sensitive, capable of detecting receptor phosphorylation
at low ligand dose and early time points. Second, even under saturating ligand
conditions, only a fraction of receptors is phosphorylated, reaching a maximum of
64% with 5 min stimulation. Third, the extent of phosphorylation varies by
tyrosine residue. The detected phosphorylation levels are not due to limitations in
antibody labeling, since cells stimulated in the presence of phosphatase
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inhibitors showed increased receptor phosphorylation (Figure 2.6A).The use of
high salt (500 mM NaCl) concentration during cell lysis did not change the
detected phosphorylation, indicating that adaptor proteins are not interfering with
antibody recognition (Figure 2.6B).

Figure 2.5. The extent of phosphorylation varies by tyrosine residue. (A) Dose
response curve for CHO-EGFR-GFP cells after 5 min of EGF addition at 37°C.
Number of receptors analyzed per condition, 800 < N < 1800. (B) Site-specific
EGFR phosphorylation kinetics. Phosphorylation time course for CHO-EGFRGFP cells stimulated with 25 nM EGF at 37°C. N>1800. Error bars are standard
error of measured phosphorylation percentages.
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Figure 2.6. Effect of phosphatase inhibition or cell lysate salt concentration on
detected phosphorylation levels. (A) CHO-EGFR-GFP cells were stimulated at
37°C with either 50 nM EGF for 5 min or pre-treated with 1 mM pervanadate (PV)
for 15 min and then stimulated with 50 nM EGF and 1mM PV (PV + EGF) for 5
min. Considering that pervanadate treatment induces EGFR phosphorylation that
may not be restricted to the plasma membrane, no surface correction was
applied for this figure. Number of receptors per condition, 690 < N < 3400. (B)
CHO-EGFR-GFP cells were stimulated at 37°C with 25 nM EGF for 1 min and
protein extraction was performed with either regular lysis buffer containing 150
mM NaCl (see Methods) or 500 mM NaCl. High NaCl concentrations have been
shown to promote disruption of interactions between SH2-containing proteins
and their phosphorylated binding partner sites (Grucza, R. A., et al.,
Biochemistry, 39(33), 10072-10081). 670 < N < 1600. Error bars are standard
error of measured phosphorylation percentages.

2.2.7 Three-color SiMPull reveals multisite phosphorylation
The observation that Y1068 and Y1173 have different phosphorylation
levels suggests that there are subpopulations of receptors with differing
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phosphorylation patterns. However, examining a single tyrosine site at a time
cannot address the coincidence of phosphotyrosines. To assess the potential of
multisite protein phosphorylation, simultaneous three-color SiMPull imaging was
developed. To test whether receptors phosphorylated at Y1068 were also
phosphorylated at other tyrosine residues, receptors were co-labeled with antipY1068 and anti-PY antibodies. When labeling a single protein with two or more
antibodies, the effects of steric hindrance must be considered. In this case,
labeling first with anti-pY1068 followed by anti-PY did not alter PY levels (Figure
2.7A). However, labeling with anti-PY first did cause a loss of pY1068 signal
(Figure 2.7B). Therefore, the experiments were performed with sequential
labeling, anti-pY1068 followed by anti-PY. As before, the addition of EGF
resulted in increased phosphorylation, with the PY antibody showing more
labeling than the site-specific antibody (Figure 2.8A,B) and the presence of multiphosphorylated receptors was observed in the three-color images (Figure 2.8A,
white circles). Figure 2.8B shows quantification of the three-color colocalization,
which revealed that ~12% of EGFR were labeled by both antibodies
(pY1068+PY,

orange

bar).

Importantly,

nearly

76%

phosphorylated at Y1068 were co-labeled with PY.
phosphorylation is a prevalent outcome in EGFR activation.
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of

the

receptors

Therefore, multisite

Figure 2.7. Assessment and correction of steric hindrance in sequentially
incubated antibodies for 3-color SiMPull. (A) Evaluation of steric hindrance
between anti-pY1068-CF555 and anti-PY-AF647 (PY) antibodies. CHO-EGFRGFP cells were stimulated with 25 nM EGF for 5 min at 37°C and EGFR
phosphorylation quantified using 3-color SiMPull. Labeling with anti-pY1068 first
did not reduce subsequent labeling by anti-PY. However, a reduction in pY1068+
receptors is seen when the labeling order is reversed. Number of receptors
analyzed per measurement, N>800. n.s. not significant, P = 0.5187. (B)
Evaluation of steric hindrance between anti-pY1068-CF555 and anti-pY1173CF640R antibodies. Cells were stimulated as described in (A) and receptor
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phosphorylation assayed by 3-color SiMPull. A reduction in labeling was
observed for the antibody that is applied second in the labeling sequence. N>780
per measurement. (C) Diagram describing estimation of correction factor (α) to
calculate actual fraction of receptors with dual phosphorylation (D’). The
observed reduction in labeling with Antibody 1 alone (left bar) as compared to
Antibody 1 following Antibody 2 (right bar) indicates the level of steric hindrance.
From this information, the correction factor can be calculated. (D) Validation of
the correction factor by exchanged labeling order. After applying the correction
factor (“Corrected” bars), the percentage of pY1068+pY1173+ receptors is
similar. Error bars are standard error of measured phosphorylation percentages.
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Figure 2.8. SiMPull reveals EGFR multisite phosphorylation. (A) Representative
3-color SiMPull image showing detection of EGFR-GFP (cyan), where receptors
positive for PY labeling appear purple and white circles mark receptors labeled
for both PY and pY1068. This image does not contain receptors labeled with
pY1068 alone. Cells were treated with 25 nM EGF for 5 min. (B) Quantification of
single and multi-phosphorylation in EGFR. Number of receptors analyzed per
condition, N>500 for resting condition and N>840 for EGF condition. (C) Stepphotobleaching analysis of multi-phosphorylated EGFR-GFP from (B). The
majority (98%) of diffraction limited GFP spots show single-step bleaching,
consistent with the pull-down of receptors as monomers. Inset shows example
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GFP-intensity trace of a multi-phosphorylated EGFR-GFP. (D) Percentage of
Y1173 phosphorylation in overall population of surface receptors compared to
that in pY1068+ receptors. N>780 for EGFR and N=51 for pY1068 EGFR. *** P <
0.001. (E) Multisite phosphorylation is also observed at lower EGF dose. Cells
stimulated for 5 min with indicated EGF dose. 970 < N < 1700 per condition.
Error bars are standard error of measured phosphorylation percentages.
To ensure receptors detected as multi-phosphorylated were individual
receptors labeled with both antibodies rather than two nearby labeled receptors
detected as one in a diffraction-limited spot, step-photobleaching analysis was
performed (Figure 2.8C). Analysis showed that the majority of doubly labeled
receptors (~98%) were associated with a single EGFR-GFP molecule (Figure
2.8C, right). It is important to note that the number of GFP spots demonstrating
two-step photobleaching increased as the sample density increased (data not
shown). Therefore, a pulldown protein density in the range of 0.04-0.08/μm2 is
recommended. Alternatively, photobleaching traces can be performed in each
measurement

to

exclude

those

spots

showing

more

than

one-step

photobleaching.
With the knowledge that the majority of pY1068+ receptors are also
phosphorylated

in

at

least

one

other

tyrosine

residue,

the

pairwise

phosphorylation of Y1068 and Y1173 was examined. In contrast to dual labeling
with pY1068 and PY (pan-pTyr) antibodies, the close proximity of these two
tyrosines did result in steric hindrance of antibody binding. This is seen as a
reduction in labeling when the antibodies are applied second as compared to first
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(Figure 2.7B). The reduced labeling efficiency measured in sequential labeling
was used to correct for steric blocking (see Figure 2.7C,D and Methods). Results
show that approximately 50% of the pY1068+ receptors are co-phosphorylated at
Y1173. This is an enrichment of approximately two-fold as compared to pY1173+
in the total EGFR population (Figure 2.8D). Stimulation of cells with lower doses
of EGF also resulted in multisite EGFR phosphorylation (Figure 2.8E). Notably, at
1 nM EGF, multi-phosphorylation is already considerable within the site-specific
subpopulations, with 58 +/- 14% of pY1068+ receptors and 29 +/- 8% of
pY1173+

receptors

being

co-labeled

with

PY.

Therefore,

multisite

phosphorylation is not merely a consequence of saturating ligand conditions. The
use of a three-color imaging scheme to correlate phospho-antibody labeling
directly with GFP-tagged receptors was critical, due to the relatively high nonspecific binding of the antibodies (Figure 2.9A,B). In the absence of the GFP
channel to remove the non-specific binding, the values for dual labeling are
underestimated (Figure 2.9C,D). These results show that SiMPull, when
performed using the improvements described here, can be used to quantify the
extent and coincidence of phosphorylation at multiple tyrosines.
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Figure 2.9. Importance of multi-color imaging for accurate quantification of
phosphorylation percentages. (A) Representative images displaying raw data
and blob-reconstructed localized molecules from a 3-color SiMPull experiment.
CHO-EGFR-GFP cells were stimulated with 25 nM EGF for 5 min at 37°C and
assayed using anti-pY1068-CF555 (yellow) and anti-pY1173-CF640R (pink)
antibodies. (B) Quantification of total number of pY1068 and pY1173
localizations per field of view when only those two channels are examined.
EGFR-GFP channel was ignored for this quantification to emulate a 2-color
SiMPull experiment. (C) Quantification of total number of pY1068 and pY1173
localizations per field of view using 3-color SiMPull. Here, the EGFR-GFP
channel was used to identify pY1068 and pY1173 localizations overlapping with
EGFR molecules, removing contributions from non-specific antibody binding. (D)
In the absence of the EGFR-GFP channel to identify receptor locations, the 2-
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color SiMPull underestimates protein multi-phosphorylation. Number of receptors
per

condition,

N>2400.

Error

bars

are

standard

error

of

measured

phosphorylation percentages.

2.3 Discussion
In this Chapter, a series of modifications to SiMPull that allow this
technique to obtain quantitative information about multiple post-translational
modifications (PTMs) at the single-protein level were described. SiMPull was
used to monitor EGFR phosphorylation patterns, quantify subpopulations of
phosphorylated

receptors, and

directly observe

the

existence

multisite

phosphorylation. This approach holds distinct advantages over other techniques.
Detailed information on protein PTMs is not accessible by traditional biochemical
methods that can only determine relative changes from an average of the
population.

While mass spectrometry has the potential to detect multisite

phosphorylation, the residues of interest must be found in close proximity
(Swaney et al., 2010). In SiMBlot, which is also a single molecule approach to
detecting PTMs, surface proteins are first biotinylated and then pulled-down via
streptavidin-coated surface, rather than by a specific antibody (Kim et al., 2016).
The SiMPull method is not restricted to surface proteins and is therefore
compatible with the interrogation of intracellular proteins.

PTMs other than

phosphorylation can also be studied as long as a suitable antibody is available.
Thus, detection of PTMs by SiMPull enables measurements that were previously
difficult to perform.
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In addition to its advantages, SiMPull has a number of caveats that must
be considered to ensure rigorous quantification. As with any antibody-dependent
technique, the affinity and specificity of the antibody must be determined.
Results showed that it is important to establish proper concentrations and
labeling times for each antibody used, as well as the importance of post-fixation
to prevent antibody dissociation during imaging. In addition, directly labeling the
primary antibody with the fluorophore eliminates the need for secondary
antibodies, which may add additional labeling efficiency artifacts and restrict
options due to the limited availability of species used to generate primary
antibodies. The phosphotyrosines probed in EGFR are located in an intrinsically
disordered region of the C-terminal tail, therefore these sites are likely to be more
accessible to antibodies than if they were located in structured regions. If the
PTMs of interest are found in structured regions, a protein denaturation step may
be used (Kim et al., 2016). Steric hindrance of two or more antibodies binding to
the same protein is another possible complication. Steric hindrance was found in
the case of co-labeling pY1068 and pY1173. However, a simple control
experiment and mathematical correction are described to avoid undercounting of
dual-phosphorylated receptors.

For future studies, the use of fluorescently-

conjugated Fab fragments may reduce the impact of steric hindrance. It is worth
noting that while detailed information on the phosphorylation status of individual
proteins status is obtained, the cell-to-cell variability is lost with SiMPull.
Using SiMPull, EGFR phosphorylation patterns were quantified. The new
level of detail afforded by SiMPull has provided several important insights. First,
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only a fraction of EGFR was found to be phosphorylated, even under saturating
ligand

conditions.

Second,

the

phospho-EGFR

is

further

divided

into

subpopulations that vary in the extent of phosphorylation at individual tyrosine
residues. Third, the use of three-color imaging allowed to probe for multisite
phosphorylation. Comparisons of pY1068 with a pan-phosphotyrosine antibody
revealed that many receptors are indeed phosphorylated at more than one
tyrosine simultaneously. Strikingly, the majority of pY1068+ receptors are colabeled with PY antibody and ~50% of pY1068+ are also positive for pY1173.
These results are in contrast to recent SiMBlot studies of EGFR concluding that
multisite phosphorylation was not a common occurrence. These differences may
be explained by optimization of our labeling protocol that provided the sensitivity
needed to detect multisite phosphorylation, including the use of fluorescentlyconjugated primary antibodies, labeling under saturating antibody conditions and
post-fixation to prevent antibody dissociation.
Notably, our results are consistent with previous work indicating that
multisite phosphorylation is important in the efficient recruitment of certain
adaptor proteins to activated EGFR (Sigismund et al., 2013; Fortian and Sorkin,
2014).

The existence of multisite phosphorylation holds significant functional

implications. By modulating protein phosphorylation patterns, both single- and
multisite combinations, downstream signaling pathways may be differentially
activated and lead to biased signaling. Consistent with this idea, it has been
shown that biased signaling arises with different ligand types and doses, as well
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as with the relative abundance of receptors and their signaling partners (Chen et
al., 2009; Wilson et al., 2012; Freed et al., 2017; Wolf-Yadlin et al., 2006).
Interestingly, dual Y1068/Y1173 phosphorylation occurred about twotimes more frequently than expected if these sites were independent of each
other, suggesting positive correlation between the sites. Mechanistically, this
enrichment could be a result of either long-lived receptor interactions or repeated
dimerization events. If dimer lifetimes are sufficiently long, then phosphorylation
of multiple sites could happen in a single dimerization event, suggesting that
phosphorylation occurs in a semi-processive manner. Alternatively, if a receptor
undergoes many dimerization and dissociation events, then these repeated
interactions could result in the phosphorylation of a unique tyrosine in each
encounter. This would be similar to quasi-processive phosphorylation as
described for ERK (Aoki et al., 2011). Experimental evidence exists to support
each of these mechanisms. Both long-lived and transient EGFR dimerization has
been observed on living cells, with dimer lifetimes dependent on ligand
occupancy (Low-Nam et al., 2011). Recent work from the Lemmon group has
shown that high and low affinity ligands induce distinct dimer structures, where
low affinity ligands lead to less stable dimers and differential signaling outcomes
(Freed et al., 2017). Oncogenic signaling by EGFR mutants has been shown to
be driven by enhanced dimerization and increased catalytic activity that could
amplify multi-phosphorylation (Kim et al., 2012; Shan et al., 2012; Valley et al.,
2015; Zhang et al., 2006).
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Interplay between receptors and the membrane environment has also
been shown to affect the efficiency of EGFR encounters (Low-Nam et al., 2011;
Chung et al., 2010). Therefore, the frequency of dimerization and the duration of
dimer lifetimes may serve as a kinetic proofreading mechanism, regulating the
EGFR phosphorylation patterns and dictating cellular outcome. Additionally,
adaptor protein binding and phosphatase activity likely play roles in
phosphorylation extent. For example, Capuani et al have shown that Grb2 and
Cbl can protect Y1045/Y1068 from dephosphorylation (Sigismund et al., 2013).
These mechanisms are not mutually exclusive and may be more or less relevant
depending on the cellular contexts. Therefore, it would be expected that
phospho-EGFR patterns will be modulated by differences in ligand dose, liganddependent dimer lifetimes, membrane architecture and adaptor protein
abundance. The contributions that these mechanisms have in EGFR and other
signaling pathways, remain unclear. The unique datasets provided by SiMPull,
combined with other experimental and computational modeling tools, should
prove useful in addressing these types of questions.
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2.4 Methods
2.4.1 Cell lines and reagents
CHO cells expressing GFP-tagged (Brock et al., 1999; Lidke et al., 2004)
or ACP-tagged EGFR (provided by Dr. Donna Arndt-Jovin) were cultured in
DMEM supplemented with 10% FBS, penicillin–streptomycin and 2 mM L-
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glutamine (Thermo Fisher Scientific). ACP-tagged EGFR was as described in
(Valley et al., 2015; Ziomkiewicz et al., 2013) with the exception that a shortened
16 aa sequence was introduced at the EGFR N-terminus (George, 2006). EGF,
Protease and Phosphatase Inhibitor Cocktail, Alexa Fluor 647 NHS Ester, and
NeutrAvidin were purchased from Thermo Fisher Scientific. CoA 488 and ACP
Synthase were purchased from New England Biolabs. N-(2-aminoethyl)-3aminopropyltrimethoxysilane was purchased from United Chemical Technologies
(#A0700). Sodium bicarbonate and sodium borohydride were purchased from
EMD Millipore (#SX0320-1, #SX0380-3). mPEG-Succinimidyl Valerate (MPEGSVA-5000-5g) and biotin-PEG-Succinimidyl Valerate (Biotin-PEG-SVA-5000500mg) were from Laysan Bio. Biotinylated anti-EGFR antibody (E101) was
obtained from Leinco Technologies. Antibodies in carrier-free buffer were
purchased from Cell Signaling Technologies:

EGFR pY1068 (clone 1H12,

2236BF) and EGFR pY1173 (clone 53A5, 4407BF). Monoclonal antibody prelabeled with AF647 to detect pan-tyrosine phosphorylation (PY99 antibody, sc7020 AF647) was purchased from Santa Cruz Biotechnology. Mix-n-Stain CF555
and CF640R antibody labeling kits were purchased from Biotium Inc.
Paraformaldehyde and glutaraldehyde were purchased from Electron Microscopy
Sciences.

2.4.2 Labeling of antibodies
Carrier-free antibodies (50 μg at 0.5-1 mg/mL per reaction) were labeled
using Mix-n-Stain antibody labeling kits following the manufacturer’s instructions.
41

Briefly, the labeling reaction was carried out for 30 min at room temperature and
antibodies were centrifuged using the ultrafiltration vial provided to remove the
unconjugated dye. Antibodies were resuspended in PBS and stored at 4 °C. The
labeling efficiency achieved was between 2.7-4.4 dyes/antibody.

2.4.3 Cell treatment and lysate preparation
CHO-EGFR-GFP cells were plated overnight in 60 mm tissue culture
dishes at 800,000 cells/dish and CHO-ACP-EGFR cells in 24-well plates at
50,000 cells/well. For ACP labeling, CHO-ACP-EGFR cells were washed with
serum-free DMEM medium (SFM), incubated with ACP labeling solution (SFM,
10 mM MgCl2, 4 μM CoA 488 and 1 μM ACP) for 20 minutes at 37°C and
washed three times with SFM previous to stimulation. Cells were washed in
Tyrode’s solution (135 mM NaCl, 10 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 10
mM HEPES, 20 mM glucose, 0.1% BSA, pH 7.2) and treated with 25 nM EGF or
Tyrode’s solution alone (resting cells) at 37°C. At the indicated time points, cells
were placed on ice, washed one time with cold PBS followed by addition of lysis
buffer (1% IGEPAL CA-630, 150 mM NaCl, 50 mM Tris pH 7.2) containing
Protease and Phosphatase Inhibitors. Cell lysates were collected using cell
scrapers (Greiner Bio-One North America, #541070), transferred to fresh tubes
on ice and vortexed every 5 min for a total of 20 min. Lysates were centrifuged at
16,000× g for 20 min at 4 °C and the supernatant was transferred to a new tube
and stored at -80 °C. For experiments involving treatment of cells with
phosphatase inhibitors, cells were pre-treated for 15 min with a Tyrode’s solution
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containing 1 mM pervanadate (PV) followed by incubation for 5 min in a solution
with 50 nM EGF and 1 mM PV. A stock solution of 30 mM PV was prepared
before each experiment by mixing equimolar concentrations of hydrogen
peroxide and activated sodium orthovanadate that was incubated in the dark for
at least 15 min before use.

2.4.4 Fabrication of hydrophobic arrays and surface functionalization
Coverglasses (24x60mm, #1.5; Electron Microscopy Sciences, #63793)
were Piranha-cleaned(Labit et al., 2008) and placed in a coverglass holder
(Fisher Scientific, #08-817). Coverglasses were sequentially sonicated in
Methanol and Acetone for 10 min each, and in 1M KOH for 20 min using a bath
sonicator (Branson Ultrasonics, B1200R-1). These solutions were stored in
polypropylene 50 mL tubes (VWR, #89401-564) and reused up to five times.
Coverglasses were rinsed with Milli-Q water two times, dried by quickly passing
them multiple times over the flame of a Bunsen burner using metal tweezers and
placed in a dry coverglass holder. A solution containing 76 mL of methanol, 4 mL
of

acetic

acid

and

0.8

mL

of

aminosilane

(N-(2-aminoethyl)-3-

aminopropyltrimethoxysilane) was prepared in an Erlenmeyer flask, immediately
poured into the coverglass holder and incubated at room temperature for 10 min
in the dark, followed by 2 min sonication and another 10 min incubation in the
dark. Coverglasses were next washed with methanol for 2 min, rinsed and
washed for 2 min with water, and dried in the dark.
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Treated coverglasses were placed on top of a parafilm-covered
coverglass containing a guide pattern, which was used as reference to draw the
Sample Array with a hydrophobic barrier pen (Vector Laboratories, #H-4000). Ink
was allowed to dry for at least 5 min before coverglasses were placed in a
humidified chamber (empty tip rack with 50 mL of water; USA Scientific #11112820). For surface functionalization, 50 mg of mPEG-Succinimidyl Valerate, 1.3
mg of biotin-PEG-Succinimidyl Valerate and 200 µL of freshly prepared 10 mM
sodium bicarbonate were mixed thoroughly by pipetting up and down, centrifuged
for 1 min at 10,000 g at room temperature and immediately applied to the
SiMPull array (10-13 uL per region). After incubating for 3-4 hours in the dark
inside the humidified boxes, arrays were washed by sequential 30 sec
submersions into three water-filled 250 mL glass beakers. Coverglasses were
dried with nitrogen gas, stored in pairs (back to back) inside 50 mL tubes, which
were filled with nitrogen gas before closing and sealing with Parafilm.
Coverglasses were stored in the dark at -20°C for up to a week before use.

2.4.5 Labeling and quantification of surface receptors
CHO-EGFR-GFP cells grown in 24-well plates were placed on ice and
washed 3 times with cold PBS. AF647-NHS Ester was dissolved at the indicated
concentrations in PBS. Cells were incubated with this solution for 30 min at 4°C
with gentle agitation, washed 3 times with cold PBS and subjected to cell lysis.
The percent of receptors labeled with AF647 across different dye concentrations
was assessed with SiMPull. To estimate the percent of receptors at the cell
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surface the AF647-labeling curve was fitted to a biexponential decay curve in its
increasing form using the ‘fit’ function in MATLAB: y = C1 (1 - e-ax) + C2 (1 - e-bx),
where y is the % of AF647-labeled receptors, x is the concentration of reactive
AF647-NHS ester used, and a>0, b>0, C1 and C2 are coefficients to be fitted.
The sum of the coefficients C1 and C2 represent the asymptote of the curve and
an approximation of the fraction of receptors at the cell surface.

2.4.6 Single-Molecule Pulldown and phospho-site labeling
T50 (10 mM Tris pH 8.0, 50 mM NaCl) and T50-BSA (T50 with 0.1 mg/mL
BSA) solutions were prepared and stored for up to a month at room temperature.
SiMPull arrays were equilibrated at room temperature and placed on a TC100
plate lined with Parafilm. Each region of the SiMPull array was treated with 10-15
µL of a 10 mg/mL sodium borohydride (NaBH4)/PBS solution for 4 min at room
temperature and washed 3 times with PBS. SiMPull regions were then incubated
with a 0.2 mg/mL NeutrAvidin/T50 solution for 5 min and washed three times with
T50, followed by incubation with a 2 µg/mL biotinylated anti-EGFR/T50-BSA
solution for 10 min and washed three times with T50-BSA.
The plate containing the SiMPull array(s) was kept on ice during sample
preparation. Lysates were diluted in cold T50-BSA with Protease and
Phosphatase Inhibitors (T50-BSA/PPI), vortexed at medium speed, and added to
the SiMPull array. After 10 min incubation, the lysates were removed and the
SiMPull regions washed 4 times with cold T50-BSA/PPI. To determine
appropriate dilution factor, the density of pulldown receptors as a function of
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lysate concentration was first assessed to achieve a pulldown density 0.040.08/μm2. Antibodies were diluted in cold T50-BSA/PPI, incubated for 1 hr,
washed 6 times with cold T50-BSA for a total of 6-8 minutes, and washed twice
with cold PBS. Immediately after, antibodies were fixed for 10 min with a 4%
PFA/0.1% GA solution (paraformaldehyde/glutaraldehyde) and washed 2 times
with 10 mM Tris (pH 7.4)/PBS for a total of 10 min to inactivate fixatives. For 3color SiMPull experiments the same antibody incubation and fixation procedure
was performed for the second antibody. Tris solution was replaced by T50-BSA
and the SiMPull array was equilibrated to room temperature before proceeding to
imaging.

2.4.7 SiMPull imaging
Imaging of SiMPull samples was performed using an inverted microscope
(Olympus America, model IX71) equipped with a 150×/1.45 NA oil-immersion
objective for Total Internal Reflection Fluorescence Microscopy (Olympus
America, UAPON 150XOTIRF) and a three-dimensional piezostage (Mad City
Labs, Nano-LPS100). Excitation of CF640R- or AF647-labeled antibodies was
done using a 642-nm laser (Thorlabs, HL63133DG), CF555-labeled antibodies
using a 561-nm laser (Coherent Inc, Sapphire 561-100 CW CDRH), and of GFPand CoA 488-tagged receptors using a 488-nm laser (Spectra Physics, Cyan
100mW). All lasers were set in total internal reflection configuration, and laser
powers were adjusted to prevent photobleaching of the sample at the timescale
of the image exposure time (300 msec). Sample illumination and emission were
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filtered using a quad-band dichroic and emission filter set (Semrock,
LF405/488/561/635-A-000). Emission light was separated into four channels
using a quad-view multichannel imaging system (Photometrics, model QV2)
equipped with the appropriate dichroics (Chroma, 495 DCLP, 565 DCLP, 660
DCLP) and emission filters (Semrock, 685/40 nm, 600/37 nm, 525/45 nm).
Emission light was collected with an electron-multiplying charge-coupled device
(EMCCD) camera (Andor Technology, DU-897E-C50-#BV) with EM gain set to
200.
Each channel was 256 x 256 pixels, with a pixel size of 106.7 nm.
Photobleaching and bleed through were prevented by controlling the laser
shutters and microscope stage through a MATLAB script to sequentially excite
and acquire the different fluorophores (642-nm laser first, 488-nm laser last). A
minimum of 20 regions of interest were acquired per condition. For quantification
of step photobleaching of EGFR-GFP molecules, a 100 frame time series (300
msec exposure time) was acquired after imaging of the other two channels.

2.4.8 Quantification of Receptor Phosphorylation
All image processing was performed using MATLAB together with the
MATLAB

toolbox

for

image-processing

DIPImage

(Delft

University

of

Technology) (Hendriks et al., 1999) and all software is available upon request.
The location of emitters in each channel was calculated using graphics processor
unit (GPU) computing as previously described (Smith et al., 2010). Fits in the
GFP channel were filtered based on the quality of the fit to the point spread
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function to reduce the chances of detecting multiple receptors in close proximity
as a single molecule. Image registration was performed as previously described
(Schwartz et al., 2017). In this work, the root mean square error for image
registration

was

<10

nm.

For

visualization

purposes,

Gaussian

blob

representations of the fluorophore localizations were generated. A receptor was
considered to be phosphorylated when the localization centers of the receptor
and labeled antibody were at a distance <106.7 nm (within 1 pixel).
Phosphorylation percentages were calculated as 100*(NPhos)/(NGFP-NBG)
where NPhos is the number of receptors identified as phosphorylated, NGFP is the
number of observed single molecules in the GFP channel and NBG is the nonspecific background rate in the GFP channel.
The number of GFP localizations was calculated by subtracting
background spots and accounting only for surface receptors as follows: NGFP =
(NLOC-NBG )*SR, where NLOC is the total number of emitters localized, NBG is the
expected number of background emitters in the area imaged, and SR (surface
ratio) is the fraction of receptors located at the cell surface. The density of
background emitters was quantified for each SiMPull array and used for
background correction of samples in that array. For 3-color SiMPull experiments
where steric hindrance between sequentially incubated antibodies was observed
(i.e. pY1068-pY1173 detection), estimations of dual phosphorylation were
corrected to account for this hindrance as explained in Figure 2.7.
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2.4.9 Statistical Analysis
Based on the consideration that the phosphorylation state of each
receptor analyzed has the properties of a Bernoulli trial, standard errors (SE) of
phosphorylation measurements were calculated as for sample proportions in a
binomial distribution: SE= p(1-p)/n, where p is the fraction of receptors
phosphorylated and n is the total number of receptors. The condition np>10 (with
the exception of Figure 2.8E, np>5) and np(1-p)>10 was ensured to be met to
allow this approximation to be adequate. Two-sample Z-test (two-tailed) was
used to estimate p-values (LeBlanc, 2004).

2.4.10 Step-photobleaching Analysis
For step-photobleaching analysis of multi-phosphorylated receptors, the
average fluorescence intensity of the area (200x200 nm) surrounding each of
these EGFR-GFP molecules was quantified and plotted for the duration of the
time series. Intensity plots were manually analyzed and the number of
photobleaching steps was quantified. For a small fraction of the emitters, the
number of molecules could not be reliably counted because either they
photobleached too quickly (<2 frames) or did not photobleach during the duration
of the movie, and therefore were excluded from the analysis.
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Chapter 3 : Building a rule-based model of the initial events of
EGFR signaling

3.1 Introduction
A number of rule-based models for EGFR signaling have been developed
in recent years, each varying in complexity and the level of mechanistic details
included (Blinov et al., 2006; Creamer et al., 2012; Kozer et al., 2013b). The
refinement of these models was mostly done using techniques that provide
ensemble or average quantitative measurements. The kind of information that
the improved SiMPull technique (described in Chapter 2) provides was not
available in the past, and therefore this model will be the first one whose
refinement is performed using this type of data. As described in following
chapters, coupling of this type of modeling and experimental data is providing
new insights about the kinetics of the molecular events involved in EGFR
activation.
The following sections present a detailed description of the development
of a model that simulate the EGF-dependent activation of EGFR, phosphorylation
of tyrosines 1068 and 1173 in the cytoplasmic tail of the receptor and the
recruitment of adaptor proteins Grb2 and Shc1 to these sites (Figure 3.1). This
model was developed using the BioNetGen language (BNGL) for rule-based
modeling (Faeder et al., 2009). The model consists of 9 reaction rules and 12
parameters. BioNetGen software was used to generate the reaction network from
these rules. The resulting reaction network consists of 39 molecular species and
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183 unidirectional reactions. The network was simulated with the deterministic
simulation engine used by BioNetGen.
In the next section, two example rules are presented to briefly describe the
basic nomenclature in BioNetGen language. A more detailed description of
BioNetGen language can be found in (Faeder et al., 2009). This is followed by a
list of the reaction rules used for this model together with a brief description.
Lastly, some of the key parameter values used in this model are enlisted, and the
source(s) of these values, if available. A complete list of the parameter values
and the file encoding the complete model can be found in Appendix B.

Figure 3.1. Graphical description of model. EGF-bound receptors can dimerize
and phosphorylated each other. This model includes the phosphorylation of
Y1068 and Y1173, and the recruitment of Grb2 and Shc1 to those respective
sites.
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3.2 Model development, Results and Discussion
3.2.1 Example reaction rules
Example Rule 1. Reversible interaction between A and B
A(domA)+B(domB)<->A(domA!1).B(domB!1) kp,km
The proteins ‘A’ and ‘B’ can interact through their domains ‘domA’ and ‘domB’,
and form a complex. Components of a complex are separated by a dot and the
molecular bonds are indicated with a ‘!’ sign and a number. For example, if more
than one molecular bond is present in a molecular complex then the bonds would
be labeled as ‘!1’, ‘!2’, ‘!3’, and so on. Note that ‘domA’ and ‘domB’ in the
reactants side do not have a ‘!’, which means that they have to be free or
unbound in order for the association reaction to occur. The forward (‘kp’ or k+)
and reverse (‘km’ or k-) reaction rates are indicated after the rule and separated
by a comma. For unidirectional reactions, only one reaction rate is specified.
Example Rule 2. Phosphorylation of protein A when it is bound (to protein B)
A(domA!+,Y1~0)->(domA!+,Y1~P) kp
Phosphorylation of ‘Y1’ can only happen if its domain ‘domA’ is bound to other
protein (‘domA!+’). In this case, protein ‘B’ can be thought as a kinase that
phosphorylates protein ‘A’ in ‘Y1’. The expression ‘!+’ in ‘domA!+’ indicates that
‘domA’ needs to be bound, regardless of to which protein it is bound to.
Alternatively, the whole complex can be explicitly specified as indicated below:
A(domA!1,Y1~0).B(domB!1)-> A(domA!1,Y1~P).B(domB!1) kp
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Only domains that are relevant to the reaction are included. For example, in the
first example rule the site ‘Y1’ was not included, because the interaction happens
regardless of the state of ‘Y1’. BioNetGen software will generate a reaction for
each possible molecular species.

3.2.2 Reaction rules
R1. EGF reversibly binds EGFR
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF
In this simple rule EGF binds to domains I and III on EGFR with a rate ‘kp_EGF’,
and dissociates with a rate ‘km_EGF’.
R2. Dimerization of EGF-bound receptors
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)->
EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b) kp_dim_L_L
EGFR that is bound to EGF (‘I_III’ domain occupied) and that has its dimerizing
domain ‘II’ unbound (‘II~u’) can dimerize with another receptor of the same kind.
The dimerization event changes the state of domain II from unbound to bound
(II~u->II~b), which is an implicit way of representing dimerization. Originally the
dimerization event was described explicitly, meaning that the two receptors
actually formed a complex. Comparing simulation results from the models that
considered dimerization implicitly and explicitly, both models behaved almost
identically (not shown), although the model with explicit dimerization had a much
higher number of molecular species and reactions. This reduced complexity of
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the implicit dimers is because they have the same number of components as a
monomer, while in explicit dimers there are twice as many components as in a
monomer. Considering that complexity increases non-linearly with the number of
components of a molecule, explicit dimers have many more possible states that
implicit dimers (for the current model a factor of 7 increase). This increase in
complexity becomes relevant when fitting the model to experimental results,
which could take days or even weeks.
Alternative versions tested: Dimerization between unliganded-unliganded or
liganded-unliganded receptors was initially considered. In this model transition of
EGFR ectodomain between tethered and extended conformations was
considered implicitly by defining a parameter that defined the probability of
receptors to be in an extended conformation (dimerization competent).
Comparing simulation results with the model that only allowed two EGF-bound
receptors to dimerize showed that they behaved very similar, and that only varied
slightly at low EGF doses (not shown). Therefore, the model was simplified and
only allow two EGF-bound receptors to form dimers. If the model is intended to
be used for studying processes at low EGF doses, like ERK activation at subnanomolar EGF concentrations, then it may be necessary to add these rules
back into the model.
R3. Dissociation of EGFR dimer
EGFR(II~b)->EGFR(II~u) km_dim_L_L
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Similarly to EGFR dimerization, dissociation of EGFR dimers was considered
implicitly, giving equal results as when considered explicitly. The dissociation
event changes the state of domain II from bound to unbound (II~b->II~u).

R4 and R5. EGFR autophosphorylation
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068
EGFR(II~b,Y1173~0)->EGFR(II~b,Y1173~P) kphos1173
Receptors that are in a dimer (II~b) can be phosphorylated with rate ‘kphos’. The
state of the tyrosine residue changes from unphosphorylated to phosphorylated
(Y~0->Y~P).
Asymmetric arrangement of the kinase domains in an EGFR dimer was not
considered for the results presented in this dissertation, but an updated version
of the model including asymmetric phosphorylation have just been created, and
will be used for the peer-reviewed publication of this work. Although the
parameters for phosphorylation rate needed to be modified for this updated
model, the simulation results from this model are very similar to the ones
obtained with the model used for this dissertation.
R6 and R7. Dephosphorylation of pY sites
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068
EGFR(Y1173~P)->EGFR(Y1173~0) kdephos1173
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Sites that are phosphorylated (Y~P) and unbound (absence of ‘!+’ sign) can be
dephosphorylated with a rate ‘kdephos’. Dephosphorylation is considered
implicitly as being constitutively active (constant dephosphorylation rate).
R8. Binding of Grb2 to pY1068
GRB2(SH2)+EGFR(Y1068~P)<-> GRB2(SH2!1).EGFR(Y1068~P!1)
kp_GE,km_GE
The SH2 domain from Grb2 binds to phosphorylated tyrosine 1068 in EGFR.
Both domains/sites must be free in order to bind.
Even though Grb2 can also bind directly to other sites, like pY1086, or indirectly
through Shc1, these interactions were not considered in this model.
R9. Binding of Shc1 to pY1173
SHC1(PTB)+EGFR(Y1173~P)<-> SHC1(PTB!1).EGFR(Y1173~P!1)
kp_SE,km_SE
The PTB domain from Shc1 binds to phosphorylated Y1173 in EGFR.
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3.2.3 Model parameters
Model parameters presented here were subsequently transformed to units of
molecules/cell and to units of seconds.
Avogadro constant (NA)
Value: 6.02214 x1023 /mol
Used to convert concentrations in molarity to concentrations in molecules per
cell.
Cytoplasmic volume (Vc)
Value: 1 picoliter
Source: Cytoplasmic volume estimated by Fujioka et al. for HeLa cells (Fujioka et
al., 2006).
Grb2 and Shc1 concentration (GRB2_total and SHC1_total)
Value: 1.0x104 - 1.0x106 copies/cell
Source: Abundance of these proteins was allowed to vary in the range specified
above for the fitting process. Naïve model was set to have values of 1.0x10 5 for
both proteins.
Number of EGFR (EGFR_total)
Value: 6.0x105 receptors/cell
Source: Value estimated previously in our laboratory for CHO EGFR-GFP cells
using flow cytometry.
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Association rate for cytoplasmic interactions (kon)
Value: 5.0x106 /M/s
Source: Assumed to be 5.0x106 /M/s for all interactions occurring at the
cytoplasm (including receptor-adaptor protein interactions).
Association rate for EGF-EGFR interaction (kon_EGF)
Value: 8.0x106 /M/s
Source: This rate was set to this value so that EGFR phosphorylation kinetics
occurs similarly to kinetics measured at high temporal resolution using mass
spectrometry (Reddy et al., 2016).
Dissociation constant (Kd) for EGF-EGFR interaction (Kd_EGF)
Value: 1 nanomolar (1.0x10-9 M)
Source: A dissociation constant of 1 nM was used for this interaction, which it is
close to previously estimated values (Björkelund et al., 2011). Dissociation rate
for this interaction was obtained using the values for kon_EGF and Kd_EGF.
Dissociation rate for EGF-bound EGFR dimers (Vc)
Value: 0.273/s
Source: Dissociation rate estimated in A431 cells by Low-Nam et al. using Single
Particle Tracking (Low-Nam et al., 2011).
Dissociation constant (Kd) for EGF-bound EGFR dimers (KD_dim)
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Value: 60,000 molecules/cell
Source: This parameter was set so that EGFR_total/KD_dim >> 1.
Dissociation constant (Kd) for Grb2-pY1068 EGFR interaction (Kd_GE)
Value: 600 nM
Source: As estimated by Morimatsu et al. using single-molecule microscopy
(Morimatsu, M., Takagi, H., Ota, K. G., Iwamoto, R., Yanagida, T., & Sako,
2007).
Dissociation constant (Kd) for Shc1-pY1173 EGFR interacton (Kd_SE)
Value: 600 nM
Source: Assumed to be the same as for Grb2-pY1068. This assumption was
based on affinity measurements for protein domains binding to phospho-peptides
of these sites showing similar affinities for Grb2-pY1068 and Shc1-pY1173
interactions (Kaushansky et al., 2008; Hause et al., 2012).
Phosphorylation and dephosphorylation rates (kphos and kdephos)
Value: 0.5-5.0 /s
Source: Allowed to vary in this range. Congruent with rates estimated by
(Kleiman et al., 2011).
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Chapter 4 : Insights on EGFR signaling by integrating
computational modeling and single molecule data

4.1 Introduction
This Chapter focuses on the integration between the experimental and
computational modeling tools developed in Chapters 2 and 3. Chapter 2
describes a series of modifications to the Single Molecule Pull-down (SiMPull)
technique to quantify the fraction of site-specific phosphorylation in EGFR. Then,
Chapter 3 describes the development of a rule-based model for EGFR signaling.
Building on those developments, SiMPull data was used to refine the rule-based
model, and vice versa, the rule-based model was used to generate predictions
that can be tested experimentally. The overall goal of this experiment-modeling
integration is to gain a quantitative understanding of the dynamic behavior of the
different processes involved in signaling.
One particular observation that the model could not initially reproduce was
the differential phosphorylation in tyrosine 1068 and 1173 of EGFR. In these
results, Y1173 consistently had higher phosphorylation levels than Y1068 at
different EGF doses and times of stimulation (see Figure 2.5 in Chapter 2). To
explore the possible origins of this behavior the rule-based model was used. The
model suggested that adaptor proteins are able to protect the phospho-sites to
which they bind from dephosphorylation, and that differences in adaptor protein
abundances could give rise to differential phosphorylation. Particularly, the model
predicted that an increase in the abundance of Grb2 would result in a higher
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percentage of receptors phosphorylated at sites to which Grb2 binds. In
agreement with this prediction, overexpression of Grb2 caused a dramatic
increase in the phosphorylation levels of a Grb2-binding site in EGFR (Y1068),
but not in a site which Grb2 does not bind (Y1173). Preliminary results suggest
that these observations using protein overexpression may translate to cells
naturally expressing different levels of adaptor proteins. Results show that
adaptor protein abundances are able to alter the phosphorylation levels of their
binding partners resulting in biased phosphorylation in vivo.

4.2 Results
4.2.1 Model can fit experimental data with only allowing adaptor protein
abundances to vary
In the previous chapter, a model of EGFR signaling was described, and
while many of the parameter values have been estimated experimentally, some
others have not. Also, it is important to consider that measurements are
approximations of the actual values and that these values likely change between
different conditions, including in which cell type the measurements were
performed. Therefore, the model parameters need to be adjusted to allow the
model to be able to reproduce experimental data. Simulation results from the
unmodified or naïve model show similar levels of phosphorylated tyrosine 1068
and 1173 (pY1068 and pY1173), while the experimental data suggests that
phosphorylation at Y1173 is higher than for Y1068 (Figure 4.1).
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Figure 4.1. Comparison of naïve model and experimental data. Percentages of
EGFR phosphorylation at tyrosines 1068 (a) and 1173 (b) after stimulation with
25 nM of EGF obtained experimentally using SiMPull (blue) or predicted by the
naïve model (red). Error bars represent mean +/- S.E.M.

There are different parameter values that can be adjusted to reproduce
the biased phosphorylation observed experimentally. Probably the most obvious
one would be to allow the phosphorylation rate in one site (Y1173) to be higher
than in the other. Another possibility is to have different dephosphorylation rates
for

each

site.

Phosphorylation

rates

measured

in

vitro

as

well

as

dephosphorylation rates measured in vivo were very similar for both sites, and
therefore could not account for the biased phosphorylation observed in our
experiments (Kim et al., 2012; Kleiman et al., 2011). A third and less obvious
possibility would be to allow the abundance of the adaptor proteins (i.e. Grb2 and
Shc1) to vary. The reason changes in adaptor protein abundances affect
phosphorylation levels in the model is because an adaptor protein bound to the
phosphorylated site protects the site from dephosphorylation by means of steric
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hindrance (Figure 4.2a). This hypothesis is supported by in vitro studies showing
the ability of SH2 domains to protect phospho-sites from dephosphorylation
(Rotin et al., 1992; Brunati et al., 1998). To test if variation in protein abundances
alone could explain the data, abundances of Grb2 and Shc1 were allowed to
differentially vary during the fitting process, while phosphorylation and
dephosphorylation were varied equally for both sites. The ability of the model to
match the experimental results based on differential abundance of adaptor
proteins supports the feasibility of this mechanism being responsible for the
biased phosphorylation observed (Figure 4.2b,c).

Figure 4.2. Fitting model to experimental data by varying adaptor protein
abundances. (a) Graphical representation of mechanism of protection of
phosphorylated sites from phosphatases by adaptor proteins. Percentages of
EGFR phosphorylation at tyrosines 1068 (b) and 1173 (c) after stimulation with
25 nM of EGF obtained experimentally using SiMPull (blue) or predicted by the
fitted model (red). Error bars represent mean +/- S.E.M.
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4.2.2 Predicted influence of Grb2 overexpression in phosphorylation levels
is observed experimentally
The fact that the model is able to simulate biased phosphorylation by
having different values for the abundances in Grb2 and Shc1 does not supports
the hypothesis that adaptor proteins are able to modulate phosphorylation levels.
Therefore, a series of predictions of the expected effect that overexpression of
Grb2 would have on the phosphorylation levels of the two sites were generated.
The model predicts that Grb2 overexpression will lead to increased
phosphorylation at Y1068, where Grb2 binds, and no change in phosphorylated
Y1173, where Grb2 is not expected to bind (Figure 4.3a,b). To test this
prediction, human Grb2-mCherry was overexpressed and its effect on EGFR
phosphorylation

was

quantified.

Consistent

with

model

predictions,

overexpressing Grb2 lead to a marked increase in the phosphorylation of Y1068,
but only a slight increase in the phosphorylation of Y1173 (Figure 4.3c,d).
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Figure

4.3.

Predicted

and

observed

phosphorylation

kinetics

in

cells

overexpressing Grb2. Predicted percentages of EGFR phosphorylation at
tyrosines 1068 (a) and 1173 (b) after stimulation with 25 nM of EGF in cells with
increasing overexpression (OE) of Grb2. Percentages of EGFR phosphorylation
at tyrosines 1068 (c) and 1173 (d) after stimulation with 25 nM of EGF in cells
expressing endogenous levels of Grb2 (orange, CHO ErbB1-GFP) or
overexpressing Grb2-mCherry (blue). Measurements were done using SiMPull.
Error bars represent mean +/- S.E.M.
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4.2.3 Model predicts cell-specific phosphorylation patterns based on
differences in adaptor protein abundances
Considering the observed ability of adaptor protein overexpression to
affect the levels of EGFR phosphorylation in a site-specific manner, it can be
hypothesized that cell types that naturally express different levels of these
adaptor proteins would display different phosphorylation patterns. Using global
and targeted proteomics two research groups recently obtained estimates for the
abundance of different proteins in different normal and cancer cell lines (Shi et
al., 2016; Kulak et al., 2014). These estimates include the protein copy numbers
(per cell) for EGFR, Grb2 and Shc1 in the non-tumorigenic mammary epithelial
HMEC and MCF10A cells, and in the cervical cancer HeLa cells (Figure 4.4a).
Simulations were performed using these values and model predictions for the
phosphorylation patterns/kinetics in these three cell lines were obtained (Figure
4.4b-d). In the HMEC cells, where the estimated abundances of both adaptor
proteins are relatively low, the model predicts similar levels of phosphorylation at
both tyrosine residues. For the MCF10A cells, the model predicts slightly higher
phosphorylation at Y1173 given that its binding partner Shc1 is expressed in
higher amounts than Grb2. The most evident difference in expression levels is
found in HeLa cells, where it is estimated that there are ~600,000 molecules of
Grb2 per cell, compared to ~100,000 molecules of Shc1 per cell. The model
predicts that phosphorylation at Y1068 would be ~1.45 times higher than at
Y1173 (Figure 4.4d). This prediction was tested experimentally in HeLa S3 cells,
where phosphorylation at Y1068 was higher than at Y1173, in agreement with
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the model prediction (Figure 4.4e). The difference in phosphorylation of these
two sites was lower than what the model predicted, with Y1068 being ~1.11 times
more phosphorylated than Y1173, compared to ~1.45 times higher pY1068
predicted by the model.

Figure 4.4. Phosphorylation patterns predicted for different cell types and
observed for HeLa S3 cells. (a) Estimation of protein copy numbers for different
cell lines estimated by Shi et al. (2016) and Kulak et al. (2014). (b-d) Predictions
of phosphorylation kinetics for different cell lines. (e) Phosphorylation pattern in
HeLa S3 cells obtained with SiMPull. Error bars represent mean +/- S.E.M.

67

4.3 Discussion
Using computational modeling and Single-molecule Pulldown, the ability of
adaptor proteins to protect phospho-sites from dephosphorylation and alter
phosphorylation levels in vivo was shown. As predicted by the model, it was
shown that overexpression of the adaptor protein Grb2 leads to increased
phosphorylation of an EGFR tyrosine residue where Grb2 binds (Y1068), while a
site where Grb2 does not strongly bind is minimally affected (Figure 4.3). The
model predicted different phosphorylation patterns for cell lines in which protein
abundances were previously estimated (Figure 4.4) (Shi et al., 2016). For
example, the model predicted that the cervical cancer HeLa S3 cells, which
express ~6 times more Grb2 than Shc1, would have higher phosphorylation
levels at the Grb2-binding site Y1068 than at the Shc1-binding site Y1173.
Experimental testing of this prediction with SiMPull showed that phosphorylation
levels are indeed higher at Y1068 than at Y1173. Nevertheless, the difference in
phosphorylation between these sites was not as high as predicted by the model.
The ability of protein domains to protect the phosphorylated residues to
which they bind from dephosphorylation has been demonstrated in vitro (Rotin et
al., 1992; Batzer et al., 1994; Brunati et al., 1998). Even though this protection
can happen in the conditions of in vitro experiments, in which high concentrations
of the reactants are generally used, less is known about the relevance of this
phospho-site protection in the context of living cells. A similar study was recently
published (Jadwin et al., 2018). In this work, they studied the quantitative relation
between Grb2 overexpression and enhancement of site-specific EGFR
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phosphorylation (7 sites analyzed) obtaining similar results to the ones presented
here. The evidence for the relevance of phospho-site protection at physiological
Grb2 expression levels presented in this dissertation should be useful information
additional to the one contributed by Jadwin et al. Also, while their computational
model collapse all the tyrosine residues into one global tyrosine, our rule-based
model has site-specific phosphorylation resolution.
The phosphorylation at Y1068 increased ~2-fold when Grb2 was
overexpressed, but little change was observed in a site where Grb2 is not known
to bind. These results support the idea that adaptor proteins are able to affect
phosphorylation levels of the sites to which they bind. In order to get a better
idea of the quantitative relation between Grb2 levels and protection of phosphosites, the concentration of Grb2 in these cells will be measured.
As mentioned before, the model predicted that HeLa S3 cells would be
~1.45 times more phosphorylated at Y1068 than at Y1173, due to its high Grb2
expression levels. Quantification of phosphorylation levels using SiMPull showed
that Y1068 phosphorylation was only ~1.11 times higher than Y1173
phosphorylation. This discrepancy may be explained by technical limitations in
the quantification of protein abundances or phosphorylation levels, however there
are other possible explanations.
It is possible that the ability of Grb2 to protect Y1068 from
dephosphorylation is being overestimated, or the ability of Shc1 to protect Y1173
underestimated, or a combination of both. Also it is important to notice that
phosphorylation levels in HeLa S3 cells are higher than in CHO cells, even when
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expression levels of EGFR are expected to be lower in HeLa cells. A possible
explanation for this could be that phosphatase activity is lower in these cells, in
which case protection by adaptor proteins would be less apparent. To distinguish
these possibilities, the phosphorylation patterns on CRISPR-engineered HeLa S3
clones lacking one or two of the copies of Grb2 or Shc1 will be measured. The
level of decrease in Grb2 and Shc1 expression of these clones will be quantified
using WB. These measurements together with the computational model will
provide with valuable quantitative information about the effect that variations in
adaptor protein abundances have on phosphorylation levels. This information
could in turn be used in combination with other experiments to explore the
relevance of this protection in downstream signaling. This may be of special
relevance in cancer cells, which often have aberrant expression levels of adaptor
proteins.
Even though the focus of this study is on the adaptor proteins Grb2 and
Shc1, these observations likely translate to other proteins binding to posttranslationally modified sites. Proteins with interaction lifetimes longer than those
of Grb2 and Shc1 may protect their binding sites with a higher efficiency than that
of these two proteins. In summary, this study has contributed to the
understanding of the interplay between different factors that modulate
phosphorylation patterns and kinetics.
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4.4 Methods
4.4.1 Simulations and parameter estimation
A complete description of the model and its parameters can be found in
Chapter 3 and Appendix B. Parameter values for adaptor protein abundances,
phosphorylation rate and dephosphorylation rate were fitted to experimental data
using the open-source software BioNetFit (Thomas et al., 2015). This software
uses a genetic algorithm to find the best fit. Configuration files for the fitting
process can be found in Appendix C. A list of the values selected by the fitting
algorithm for each parameter is presented in Table 1.

Table 1. List of parameter values selected by fitting algorithm (Chapter 4)
Parameter
Grb2 concentration
Shc1 concentration
Phosphorylation rate
Dephosphorylation rate

Parameter Value (fit)
3.51 x104 molecules/cell
4.72 x105 molecules/cell
0.62 /s
1.83 /s

4.4.2 Single Molecule Pull-down experiments
For methods and reagents in SiMPull experiments please refer to Methods
section in Chapter 2.
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Chapter 5 : A computational model of differential signaling
induced by EGFR ligands

5.1 Introduction
In this chapter, a computational model that could explain differential
signaling induced by EGFR ligands is described. Wilson et. al. observed that
stimulating cells with saturating concentrations of different ligands lead to distinct
cellular outcomes, with the low-affinity ligands epigen and epiregulin inducing
greater cell proliferation than the high-affinity ligand EGF (Wilson et al., 2012).
Using protein crystallography, FRET assays and Single Particle Tracking
(performed by me and Dr. Diane Lidke), Freed et al. showed that the epigen and
epiregulin induced a dimer structure that lacked some key interactions which are
present in the EGF-induced dimers, leading to less stable EGFR dimers (Freed
et

al.,

2017).

These

differences

had

an

effect

in

receptor

phosphorylation/degradation and in both ERK and Akt activation, with
epigen/epiregulin stimulation leading to sustained signaling, and EGF-induced
activation having a more transient behavior, with signaling being almost
completely null by 90 minutes. The fact that these experiments were carried out
at saturating ligand concentrations, and that another low affinity ligand
(amphiregulin) showed transient EGFR phosphorylation similar to the one
induced by EGF, supported the idea that the differential response elicited by
these ligands was due to changes in receptor stability rather than in ligandreceptor affinity. The differences in signaling kinetics were also reflected in
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cellular outcomes, with epigen and epiregulin leading to cell differentiation after
long-term incubation with these ligands, and with EGF inducing cell proliferation.
The difference in signal downregulation observed for these ligands may be
due to a combination of multiple factors, including differences in the ability to
recruit protein phosphatases and differences in receptor trafficking. Liganddependent trafficking of EGFR has been previously reported; for example, TGF-α
seems to preferentially induce EGFR recycling to the plasma membrane allowing
for sustained ERK activation, whereas EGF promote receptors to be directed to
the lysosomal pathway for degradation (Francavilla et al., 2016; Roepstorff et al.,
2009).
The fate of EGFR after activation is also dependent on ligand
concentration. For example, previous work suggests that low doses of EGF
induce receptor internalization almost exclusively through clathrin-mediated
endocytosis (CME), leading to relatively low levels of receptor degradation and
high recycling (Sigismund et al., 2008). At high doses of EGF, a fraction of the
receptors internalize also through CME, but another fraction internalizes through
a type of non-clathrin mediated endocytosis that promotes receptor degradation.
This type of endocytosis was shown to be dependent on ubiquitination of EGFR
(Sigismund et al., 2005). One of the main proteins responsible of EGFR
ubiquitination is the E3 ubiquitin ligase Cbl, which can be recruited directly to
phosphorylated Y1045 in EGFR or indirectly through Grb2, with which Cbl forms
a complex (Waterman, 2002). EGF dose-response curves of EGFR ubiquitination
showed that receptor ubiquitination levels are low when EGF concentration is
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below a threshold (3-10 ng/mL EGF in HeLa cells), and high after this
concentration threshold is surpassed (Sigismund et al., 2013). On the other
hand, receptor phosphorylation showed a more gradual increase as a function of
EGF concentration. This behavior seems to happen at the plasma membrane, as
it was unaffected by inhibition of receptor endocytosis by dynamin knockdown.
Their results supported a mechanism in which Cbl-Grb2 complex is recruited in a
cooperative fashion to receptors with dual phosphorylation at the Cbl and Grb2
recruiting sites (pY1045-pY1068). This hypothesis was further supported by
testing a computational model of Cbl-Grb2 cooperative recruitment and
ubiquitination based on quantitative measurements (Capuani et al., 2015).
Consistent with previous results, receptor ubiquitination levels directly related to
endocytosis of the receptor through non-clathrin mediated endocytosis, leading
to degradation.
Using this information, it can be hypothesized that if dimer lifetimes
induced by epiregulin or epigen are not long enough to result in significant
simultaneous phosphorylation at Y1045 and Y1068, then only a few Cbl-Grb2
complexes will be recruited. This, in turn, would lead to lower receptor
ubiquitination and signal downregulation as compared to EGF stimulation. To
help guide experimental efforts in testing this hypothesis, the computational
model described in Chapter 3 was extended to include cooperative recruitment of
Cbl and receptor ubiquitination, and to account for differential dimer stability
induced by EGFR ligands. The model predicts that, in cells with low to moderate
levels of EGFR, epiregulin will induce notably less ubiquitination than EGF and
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explain

the

different

signaling

outputs

observed.

In

combination

with

experiments, this model is expected to improve the quantitative understanding of
the processes involved in differential signaling by different EGFR ligands.

5.2 Results
5.2.1 Model reproduces Y1068-Y1173 dual phosphorylation measured
experimentally
Before

proceeding

to

extend

the

model

to

account

for

multi-

phosphorylation at the tyrosine pair relevant for Cbl recruitment and
ubiquitination (Y1045-Y1068), the performance of this model was tested for its
ability to reproduce phosphorylation levels of the Y1068-Y1173 pair, for which
SiMPull data was already available. Up to this point the data that have been used
for training and testing the model come from 2-color SiMPull experiments, in
which the phosphorylation state of a single specific tyrosine residue is
determined. Therefore, the model does not provide information about
simultaneous phosphorylation at multiple sites. Chapter 2 describes an improved
protocol to allow detection of receptor multi-phosphorylation using 3-color
SiMPull. In those experiments, the receptors were co-labeled with spectrally
distinct antibodies for pY1068 and pY1173, and the percent of receptors with
simultaneous phosphorylation at these two sites was estimated. The model
predicted that ~6.8% would be phosphorylated in both sites (Figure 5.1a). The
percentage of dual phosphorylation estimated experimentally was similar to that
predicted by the model (~6.8% vs ~7.2%, Figure 5.1). These results show that
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the model is capable of making congruent predictions about dual phosphorylation
when provided with single-site phosphorylation data of two sites.

Figure 5.1. Predicted and observed dual Y1068-Y1173 phosphorylation. (a)
Prediction of EGFR phosphorylation at sites Y1068, Y1173, and dual
phosphorylation at these sites (pYpY). (b) Graphical representation of 3-color
SiMPull for the analysis of individual and simultaneous phosphorylation at Y1068
and Y1173. (c) 3-color SiMPull results for EGFR from CHO EGFR-GFP cells
stimulated with 25 nM of EGF for 5 minutes. Error bars represent mean +/S.E.M.

5.2.2 Extended model for ubiquitination is able to reproduce experimental
behavior
The model was extended to include some of the events that impact EGFR
ubiquitination levels at the plasma membrane: phosphorylation of tyrosine 1045,
direct recruitment of Cbl to pY1045, indirect recruitment of Cbl through the Grb2
and ubiquitination of EGFR by Cbl. The model also considered the cooperative
recruitment of the Cbl-Grb2 complex to receptors phosphorylated at both Y1045
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and Y1068 (Sigismund et al., 2013; Capuani et al., 2015). The current idea
behind this observed cooperativity is that, when a Cbl-Grb2 complex is bound to
one site in a dually phosphorylated receptor, the chances of (re)binding to the
other site increases due to the increased proximity or local concentration. This, in
turn, results in a significant increase in the time that the complex remains bound
to these receptors.
To capture this behavior in the model, the association constants of Cbl
and Grb2 to the phosphorylated receptor are multiplied by a cooperativity
constant (𝒌𝒄) in the reactions where the complex is already bound to the receptor
and the other tyrosine residue is phosphorylated and unoccupied (Figure 5.2). In
a similar way, if the Cbl-Grb2 complex breaks while both Cbl and Grb2 are bound
directly to the receptor the association constant for Cbl-Grb2 is multiplied by 𝒌𝒄.
Grb2 can also be recruited to tyrosine 1086 and contribute to the cooperative
behavior. Comparison of a model containing one or two Grb2-binding sites
showed that both models could fit the experimental data equally well. Thus, only
one Grb2 binding site was considered in the model. The model also considers
that the number of Cbl molecules available for binding to the receptor is generally
low (~5,000-10,000 molecules/cell) compared to other adaptor proteins like Grb2
(~1.0x105 to 1.0 x106 molecules/cell) (Shi et al., 2016; Capuani et al., 2015).
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Figure 5.2. Graphical description of reactions included in extended model to
consider cooperative Cbl recruitment. 𝒌𝒄 represents the cooperativity constant to
account for increased local concentration. For simplification, the dissociation of
the Cbl-Grb2 complex while bound to EGFR is not depicted, but in the actual
model these reactions were included.

The model was fitted to the dose-response curves of WT receptor
ubiquitination and phosphorylation in response to EGF in HeLa cells reported by
Sigismund et al. (2013). The dataset for ubiquitination of an EGFR mutant
lacking the sites for Grb2 recruitment (Y->F mutations) but having Y1045
(Y1045+) was also included for fitting the model. All parameters shared by the
previous and extended models were kept at the same value and the parameters
unique to the extended model were estimated (see Methods). As observed in
Figure 5.3, the model was able to reproduce all three experimental dataset fairly
well, with ubiquitination increase happening at lower EGF doses than
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phosphorylation, and with ubiquitination in the Y1045+ mutant receptor being
drastically lower than in the WT receptor (Figure 5.3a and Figure 5.3b,
respectively). Notice that the ubiquitination levels in the model are low (~2%,
solid red line in Figure 5.3b). The model was unable to yield a good fit for higher
ubiquitination levels.

Figure 5.3 Fitting model to experimental data. Comparison of model simulations
(solid lines) to the experimental data (dashed lines) used for the fitting. (a) Doseresponse curve for receptor phosphorylation at tyrosine 1068 (pY) and
ubiquitination (Ub) in cells expressing WT EGFR. (b) Ubiquitination curve for WT
and mutant receptor devoid of the sites for Grb2 recruitment but containing the
site for direct recruitment of Cbl (Y1045+). Data obtained from Sigismund et al.
(2013).

To validate the model, knockdown (KD) of EGFR was simulated and the
ubiquitination dose-response curve from simulation results were compared to the
experimental data obtained by Capuani et al. (2015) (Figure 5.4a). Consistent
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with experimental results, model simulations showed that decreasing the number
of EGFR molecules would result in a shift to the right of the ubiquitination curve.
The reason for this behavior is that the number of receptors with dual
phosphorylation at Y1045-Y1068 in the EGFR KD cells is much lower than in WT
cells, and needs higher EGF concentrations to induce an enough receptors to be
dually phosphorylated (and recruit Cbl efficiently) (Figure 5.4b).
When looking at the fraction of receptors ubiquitinated instead of the
values normalized to the maximum in Figure 5.4c, it can be observed that the
model predicts the ubiquitination percentage to be higher in cells with fewer
receptors (EGFR KD, 50x103 receptors) than in WT cells (250x103 receptors).
This is consistent with the results of Capuani et al. (2016) and the idea that Cbl is
present at a limiting concentration. To additionally validate the model, the effect
of Cbl overexpression in receptor ubiquitination observed in this model and
experimentally were compared (Figure 5.4d). Consistent with experimental
results, an increase in the concentration of Cbl resulted in higher ubiquitination
levels but did not result in a shift of the curve to the right or left. It is important to
mention that, while this model reproduced most datasets, it was not able to
completely match the dual phosphorylation curve at Y1045-Y1068 measured
using co-IP WB by Sigismund et al. (2013) (Figure 5.4e).
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Figure 5.4. Model validation: Ubiquitination in cells with EGFR knockdown or Cbl
overexpression. Solid lines represent results from model simulations and dashed
lines from experimental results from the literature. (a) Knockdown (KD) of EGFR
was simulated by a 5-fold decrease in the number of receptors per cell. (b) pYpY
refers to pY1045-pY1068 pair. Dark line indicates the number of Cbl per cell in
the model (5,000/cell). (c) Same as (a) but not normalized to maximum
ubiquitination. (d) Cbl overexpression was simulated as a 2-fold increase in the
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number of Cbl molecules per cell. (e) Comparison of dual phosphorylation in the
model and in experimental results by Western blot.

5.2.3 Model predicts impaired ubiquitination in epiregulin-stimulated MCF7
cells
The validated model was used to predict the effects that differences in
ligand-dependent dimer lifetimes would have in receptor ubiquitination. Even
though in vitro and in vivo studies suggested an important decrease in the
stability of epiregulin-induced dimers, dimer off-rates for this condition have not
been reported (Freed et al., 2017). Single-Particle Tracking measurements of
EGFR dimer off-rates previously performed by Low-Nam et al. in our laboratory
suggest that the off-rates of singly EGF-bound dimers is ~9 larger (less stable)
than that for doubly EGF-bound dimers in HeLa cells (Low-Nam et al., 2011).
Taking this information into consideration, as a starting point a 4 times larger
dissociation rate for epiregulin-induced dimers than for dimers bound to two
molecules of EGF was used in the model. On rates (dimerization rates) were
assumed to be the same for EGF- and epiregulin-bound receptors. To simplify
direct comparison of ubiquitination as a function of fraction of ligand-bound
receptor, ligand concentration and affinity were kept the same for both ligands.
Simulation results suggest that shorter-lived epiregulin dimers would not
be able to induce as strong of ubiquitination as EGF dimers, even at saturating
ligand concentrations in MCF7 cells, which express low levels of EGFR (Figure
5.5a). Reduced receptor ubiquitination could result in less EGFR downregulation
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and a more sustained signal, as observed experimentally for epiregulin and
epigen. The predicted ligand-dependent differences in receptor phosphorylation
can be observed in Figure 5.5b.

Figure 5.5. Predicted ubiquitination and Y1068 phosphorylation levels in MCF7
cells when stimulated with EGF vs epiregulin. Levels of EGFR were set to 5,000
receptors/cell to simulate low expression levels of EGFR observed in MCF7.

5.2.4 Using the model to help identify the mechanisms contributing to
epiregulin-induced sustained signaling
Even if receptor ubiquitination is significantly lower in epiregulin-treated
cells than in those stimulated with EGF, as predicted by the model, this would not
rule out the possibility that other mechanisms are responsible for the prolonged
EGFR signaling observed upon stimulation with high doses of epiregulin.
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Therefore, the model was used to explore if there was a cellular context in which
high doses of epiregulin were expected to achieve a similar level of receptor
ubiquitination as doses of EGF that induce transient signaling.
Since expression levels of EGFR were shown to alter the dose-response
curve of receptor ubiquitination (see Figure 5.4a and (Capuani et al., 2015)), the
number of receptors per cell in the model was modulated and the predicted
ubiquitination curves for EGF and epiregulin for these cellular contexts were
simulated (Figure 5.6, top). The model predicts that as EGFR expression is
increased the ubiquitination and phosphorylation response for EGF and
epiregulin become more similar, especially at saturating ligand concentrations. If
these predictions are confirmed and ubiquitination is responsible for differential
signaling, it would expected both ligands to induce similar signaling kinetics (i.e.
transient behavior). If, instead, epiregulin-induced signaling continues to be
sustained

even

when

having

similar

levels

of

receptor

phosphorylation/ubiquitination as EGF-activated receptors, it may suggest that
sustained signaling is likely originated by another distinct property induced by
epiregulin (e.g. ligand-receptor stability in endosomes).
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Figure

5.6.

Predicted

EGF-

and

epiregulin-induced

ubiquitination

and

phosphorylation different EGFR expression levels. The model predicts that as
EGFR expression levels increase, EGF vs EREG difference is less notorious.

5.3 Discussion
Previous experiments by Roepstorff et al. showed recycling of EGFR
when stimulated with epiregulin (Roepstorff et al., 2009). Nevertheless, these
experiments were carried out using a ligand concentration of 100 nM, which
compared to the concentration necessary to elicit half maximum receptor
phosphorylation in cells (20 μM) would be considered a non-saturating
concentration (Freed et al., 2017). Therefore, it is unknown how much receptor
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recycling and degradation is induced by high doses of ligands such as epigen
and epiregulin.
Our model predicted that only a low fraction of receptors (2-6%) are
ubiquitinated at the plasma membrane level at early time points (e.g. 2 min)
(Figure 5.3b, and top of Figure 5.6). A set of parameters values could not be
found that resulted in higher ubiquitination levels and still fit adequately the
experimental results. An explanation may be that in the model the stability of the
Cbl-Grb2 complex to dually phosphorylated receptors needed to be relatively
high (half-life > 20 seconds) in order to fit to the observed ubiquitination curves.
The slow unbinding of this complex would limit the number of different receptors
to which it can bind at short timescales. SiMPull assay is going to be used to test
whether indeed only a small fraction of receptors is ubiquitinated at this time
point.
It is possible that only a low fraction of ubiquitinated receptors is needed to
induce non-clathrin mediated endocytosis (NCE) of both ubiquitinated and nonubiquitinated receptors. It is also possible that Cbl is able to ubiquitinate not only
the receptor to which it binds but also receptors to which it dimerizes, or nearby
receptors in the same microdomains at the plasma membrane. It was estimated
that ~22% of receptors are ubiquitinated in at least one site of EGFR after 5
minutes of stimulation with a relatively high dose of EGF (20 ng/mL) (Huang et
al., 2013). Considering that Cbl will continue to induce receptor ubiquitination
after being endocytosed (Umebayashi et al., 2008), it is feasible that only a small
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fraction of receptors is ubiquitinated at the membrane, as represented in our
model.
Our model suggested that at higher receptor concentrations than the ones
tested experimentally (~5x103 - 50x103 receptors/cell) by Freed et al. (2017),
there would be a dose of epiregulin that would induce similar levels of
cooperative recruitment of Cbl and receptor ubiquitination as those induced by
EGF at some other dose (Figure 5.6, top). It may be possible that sustained
signaling kinetics by epiregulin will still be observed in these conditions. If that is
the case, one possible explanation would be that the nature of the ubiquitination
induced by epiregulin and EGF may be different (e.g. different levels of mono- vs
poly-ubiquitination), even if the total ubiquitination measured is similar. Another
possibility may lie in differences in receptor trafficking induced by factors other
than ubiquitination, such as stability of the ligand-receptor complex inside
endosomes. This could happen either by changes in endosomal pH or by ligand
unbinding at endosomes, as suggested for the high-affinity ligand for EGFR TGFα and the low-affinity ligand for EGFR amphiregulin, respectively (Ebner and
Derynck, 1991; Roepstorff et al., 2009).
Quantitative measurements will be performed to test the predictions made
by the computational model. This will contribute to gaining mechanistic insights
about the processes involved in differential signaling induced by EGFR ligands.
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5.4 Methods
5.4.1 Simulations and parameter estimation
Parameter values used in the fitted model of the previous chapter were
used for the extended model presented here. A complete list of parameters and
reaction rules used for this model can be found in Appendix B. A list of the
parameters fitted using BioNetFit for this model, and the values selected by the
fitting algorithm, can be found in Table 2. Configuration files for the fitting process
can be found in Appendix C.

Table 2. List of parameter values selected by fitting algorithm (Chapter 5)
Parameter
Parameter Value (fit)
Kd Cbl-pY1045*
2.51 x10-7 M
Kd Cbl-Grb2
7.24 x10-7 M
Cooperativity constant
2.59 x108
Ubiquitination rate
5.26 x10-2 /s
Deubiquitination rate
1.71 x10-2 /s
* Kd Cbl-pY1045 means dissociation constant (in molar units) between Cbl and
pY1045 in EGFR.
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Chapter 6 : Implications and Future Studies

6.1 Implications
6.1.1 Significance of improvements made on SiMPull technique
The improvements made on the SiMPull technique allows for the
quantification of the heterogeneity in the activation states of single molecules.
The majority of the proteins involved in signaling have multiple sites of
phosphorylation and other post-translational modifications. Therefore, these
improvements should prove useful in the study of other signaling players.
Additionally, some of the improvements made for quantification of receptor
phosphorylation, like reduction of background fluorescence, can be useful for
when doing traditional SiMPull where the intention is to quantify the
heterogeneity in composition of protein complexes.

6.1.2 Significance of understanding role of adaptor protein abundances in
biased phosphorylation
By studying the quantitative relation between adaptor proteins and
phosphorylation, the quantitative understanding of the different factors affecting
phosphorylation levels has been improved. This information can be included in
future computational models to have a more realistic representation of the
processes modulating phosphorylation. The understanding of the phospho-site
protection mechanism described could also help interpreting results in which
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variations in protein abundances are involved, as the possibility of protection
from phosphatases is not commonly considered. For example, if the
phosphorylation levels of two sites are correlated, one hypothesis would be that
phosphorylation of one site promotes the phosphorylation of the second, or vice
versa, as hypothesized by Coba et al. when observing correlation between
phosphorylated sites of a neuronal signaling pathway (Coba et al., 2009). But it
can also be that the correlation is due to an adaptor protein protecting two nearby
sites from dephosphorylation. Additionally, understanding the relation of adaptor
protein abundances and phosphorylation could help understand what happens in
cancer cells that overexpress certain adaptor proteins.

6.1.3 Significance

of

rule-based

model

for

EGFR

activation

and

ubiquitination by different ligands
By testing the predictions generated by the model described, it is expected
that a better mechanistic understanding of differential signaling induced by EGFR
ligands will be gained. Understanding how dimer lifetimes translates into different
signaling outcomes can be helpful in understanding differences in signaling
observed with other ligands, or in other membrane receptors whose binding
lifetimes are different to those of EGFR. The rule-based model created in this
work can be adapted to represent activation of these receptors. Additionally, this
knowledge can be useful in designing intelligent modulators of signaling protein
interactions to promote signal downregulation in diseases such as cancer.
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6.2 Future Studies
6.2.1 Effects of adaptor protein abundances in downstream signaling and
cellular outcomes
To gain a deeper quantitative understanding of the relationship between
protein abundances and phosphorylation levels, our team is generating a series
of HeLa S3 clones in which one or two copies of the genes encoding for Grb2
and Shc1 have been knocked out using CRISPR engineering.
Cancer cells commonly have altered expression of signaling proteins.
Therefore it would be interesting to know what the effects of these alterations in
signaling are. For example, the ERK pathway has been shown to be activated at
very low doses of EGF, therefore it would be interesting to know if Grb2
overexpression leads to ERK activation happening at even lower doses, or if it
makes the activation stronger. When looking at the effect of protein
overexpression, it is difficult to distinguish how much of the observed effect is
due to protein availability itself and how much due to site protection. To evaluate
these contributions, a model where sites are not protected by adaptor proteins
could be created.

6.2.2 Experimental

testing

of

model

predictions

for

differential

ubiquitination induced by EGFR ligands
Measurements of ubiquitination levels in MCF7 (~5,000 receptors/cell) or
T47D (~50,000 receptors/cell) cells in response to saturating concentrations of
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EGF and EREG will be performed, in order to see if, as predicted by our model,
differential ubiquitination is observed. These measurements could be performed
first by Western blot and if a difference is observed, then SiMPull experiments for
ubiquitination can be performed. This would provide the percent of receptors
ubiquitinated and would be very useful to compare with the current model, which
predicts low ubiquitination percentages (2-6%). Another experiment that would
provide useful information to refine the model would be to measure
phosphorylation at Y1045 with SiMPull. The anti-pY1045 antibody is available in
the lab and it will be labeled for use in SiMPull experiments in the near future.
Also, it is likely dual phosphorylation at Y1045-Y1068 with SiMPull will be
performed. Considering the close proximity of these sites, there may be problems
with steric hindrance between these antibodies, in which case, Fab fragments
could be generated to decrease chances of steric hindrance.
Additionally, it is going to be tested if phosphorylation and ubiquitination
induced by the two ligands become more similar in cells expressing higher levels
of receptors, as predicted by the model. If that is the case, then it would be
interesting to check if the signaling kinetics is also similar (i.e. transient),
supporting the role for ubiquitination in biased signaling. If that is not the case,
other mechanisms may be involved, for example differences in ligand-receptor
stability in endosomes. EGF has been shown to still induce strong
phosphorylation in early endosomes (Francavilla et al., 2016), but if EREG
stability decreases in endosomes it could be expected to have lower
phosphorylation in early endosomes, and likely increased receptor recycling. This
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can be tested by using confocal microscopy by labeling for markers of early
endosomes (e.g. Rab5) and EGFR phosphorylation, and also labeling for
recycling markers (e.g. Rab11).

6.2.3 Study phosphorylation and downstream signaling of EGFR mutant
L858R
The L858R EGFR mutant, involved in Non-Small Cell Lung Cancer, has
been shown to have increased kinase activity and increased dimer stability
(Zhang et al., 2006; Valley et al., 2015). It would be interesting to explore what
are the effects of these altered kinetic parameters in biased phosphorylation and
in receptor multi-phosphorylation. Preliminary results using 3-color SiMPull show
that even though the levels of phosphorylation increase, the biased
phosphorylation still remains (Figure 6.1).

Figure 6.1. Single- and multi-phosphorylation in WT vs L858R mutant receptor.
Receptors expressed in CHO cells. Receptors were labeled using an anti-pY
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(pan-pY) antibody. An anti-EGFR antibody will be used in future experiments to
label the receptors. Error bars represent mean +/- S.E.M.
It would also be relevant to understand how dual phosphorylation at
Y1045-Y1068 and receptor ubiquitination is affected in the mutant receptor.
Shtiegman et al. showed that Cbl recruitment to L858R EGFR and receptor
ubiquitination were decreased compared to WT, even when Y1045 and Y1068
were more phosphorylated (Shtiegman et al., 2007). Their results suggest that
by favored heterodimerization with HER2 this mutant evades Cbl recruitment and
ubiquitination. It would be interesting to know if receptor ubiquitination is
increased in this mutant in the absence of HER2, and explore how these
changes affect downstream signaling and cellular outcomes.
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APPENDIX A: MATLAB scripts for analysis of SiMPull data
This script was used to localize and process SiMPull data.

% Script to overlay fitting in 2 channels
close all;
clear all
clear dat

% Instructions: copy this script inside a 'scripts' folder located in
the
% same location as the files to be analyzed. Copy correct channel
% registration file name. Set threshold for the 3 channels (488 topright,
% 561 top-left, and 642 bottom-left; use
% thresholdTest.m to assess your decision). Use joinSequentialCh to
join
% the 3 channels in single images (it creates "joined_" files). Use
formatFilenames.m to create
% list of files ("joined_" files) and 4D-dipimage to assess frames that
should be excluded for
% analysis (bad frames).
% This version (v2_03) allows definin the min P value to filter fits
for
% each individual channel. Therefore you can filter out only irregular
GFP
% molecules that are probably more than one receptors in close
proximity
% This version (v2_02) saves the coordinates of the triple overlay GFP
% molecules in the variable 'coordTripleOv'.
% This version (v2_01) got significantly modified in order to be able
to
% use the new Registration Class that Mark wrote. In order to analyze
the
% fiducial (now acquired using nanogrid) you should use Matlab 2015a or
% later versions.
% This version (v1_04) don't sum the frame selected and the previous
one,
% only the frame specified, given that now we are using an automated
% process for the data acquisition and the shutters from the lasers and
the
% camera are coordinated.
% This version (v1_05) take first image in from right channel and
second
% from left channel because for some reason the green laser (right ch)
started
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% turning on from the first frame acquired (frame 0), when normally is
from
% the second frame (frame 1)
% This version (v1_06) is the v1_05 adapted to get the fields of view
from
% the new QuadView setting. These fields of view are of 256x256 (double
% than before) and we image only 9 fields of view instead of 36.
% This version (v1_06_3color) is the v1_06 adapted to analyze and
overlay
% the 3 channels (488 top-right, 561 top-left, and 642 bottom-left)
% This version (v1_07_3color) fixed some errors
% v1_06_3color had in quantifying % of 561 spots with overlapping 642,
and
% included quantification for overlapping of spots of the three
channels
% (triple overlap)
% This version (v1_08_3color) is the v1_07_3color adapted to analyze
and overlay
% the 3 channels (488 top-right, 561 top-left, and 642 bottom-left)
% acquired with the new laser and instrumentation class. Here the 3rd
% dimension indicates the number of frame or field of view, and the 4th
% indicates the 3 different channels/lasers (642 first, 561 second and
488
% last, acquired sequentially to prevent bleed through and bleaching).
% Version v1_09_3color is v1_08_3color but with higher P value
threshold to
% prevent considering very bright crap that fluoresces in 2 or 3
channels
% and that would be otherwise considered phospohrylated receptors. (P
value
% changed to
instead of 0.0)

intperframe_488= 700; % Intensity to use for thresholding per frame in
the respective channels.
intperframe_561= 600;
intperframe_642= 200;
minPValue_488= 1e-99;%1e-99;2e-1 % Minimum P value for filtering
fits(the bigger the more fits will reject)
minPValue_561= 0;%1e-99; % Minimum P value for filtering fits(the
bigger the more fits will reject)
minPValue_642= 0;%1e-99; % Minimum P value for filtering fits(the
bigger the more fits will reject)
% define files
cd .. % change current directory to one level up
filedir= pwd; % use current directory as filedir
% filedir='E:\Emanuel\DATA\SiMPull\150803 CHO EGFR-GFP A647-NHS-ester
surface';
paramsfile=[filedir '\scripts\SPTparams.mat'];
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% Create folder to save files for tracking
savedir=fullfile(filedir,'totrack');
if ~exist(savedir, 'dir')
mkdir(savedir);
end
% Create folder to save files to save figures
savedirFigs=fullfile(filedir,'Figures');
if ~exist(savedirFigs, 'dir')
mkdir(savedirFigs);
end
% Defined location and name of Registration Analysis files
regAnal561file=[filedir '\fiducial\RegAnal_A488_561.mat'];
regAnal642file=[filedir '\fiducial\RegAnal_A488_642.mat'];

% Set file info

% Small sample of files for dissertation
dat(1).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-45-13';
badFrames{1}= [];
dat(2).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-47-29';
badFrames{2}= [1];
dat(3).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-47-51';
badFrames{3}= [];
dat(4).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-48-11';
badFrames{4}= [1:3];
dat(5).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-48-50';
badFrames{5}= [1];
dat(6).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFRAF555_pY1068-CF640R-2018-2-1-17-49-48';
badFrames{6}= [1 2];

for iiDat=1:length(dat)

97

goodFrames{iiDat}= 1:3; % Initialize good frames (it doesn't take
consider first and last frame (0 and 4) because they are used for
focusing)
goodFrames{iiDat}([badFrames{iiDat}])= []; % Remove bad frames
for iiFrame=1:length(goodFrames{iiDat})
dat(iiDat).frms{iiFrame}=goodFrames{iiDat}(iiFrame); % create
structure with frames to be analyzed
end
end

% Load Registration Analysis files and get transformation function
% Transform 561 based on 488
load(regAnal561file)
SXS = RA.SensorXSplit;
% channel 2 x-coordinates should be > SXS
% Construct the mapping from the right channel to the left.
% Note that mapping occurs in absolute coordinates.
% Optimal map:
M561 = RA.getOptimalMapPixels();
% Maps by algorithm:
%
(1) Null
%
(2) GlobalAffine
%
(3) LocalAffine
%
(4) SmoothAffine
%
(5) LWM
%
(6) Polynomial
%
(7) NRS
%M = RA.maps(5).mapFunctionPixels;
% Transform 642 based on 488load(regAnal561file)
load(regAnal642file)
SXS = RA.SensorXSplit;
% channel 2 x-coordinates should be > SXS
M642 = RA.getOptimalMapPixels();

totFrms= 0; % Initialize total number of frames to be analyzed
% Calculate total number of frames to be analyzed
for ii=1:size(dat,2)
totFrms= totFrms+size(dat(ii).frms(:),1);
end
% Before looping through initiate define column identifiers and
'valuecell'
% to store the numbers of found fits
% define column identifiers
colIdent= {'FileName', '488-fits','561-fits','642-fits',...
'488-561-overlaps','488-642-overlaps','561-642-overlaps','Tripleoverlap',...
'% 488 w/561','Average %','% 488 w/642','Average %','% 488 w/561642','Average %',...
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'% 488-561 w/642','Average %','% 488-642 w/561','Average %'};

valuecell= cell(totFrms+1,numel(colIdent));
valuecell(1,:)= colIdent;
absFrameNum= 0; % Absolute frame number (to correctly place info in
cell array 'valuecell')
blnk=dip_image(zeros(256,256)); % Blank image used in the process of
building gaussian blob images
% loop through each movie defined above
for ii=1:size(dat,2)
load(fullfile(filedir,dat(ii).filename));
% because sequence var gets re-written need to rename, Now
% I'm using dataset instead of sequence so this renaming may
% be unnecesary in the future
for jj=1:length(dat(ii).frms)
clear sptObj642 sptObj488 test currfrms image_out c svfilename
TrackXY642 TrackXY488 tots488 tots642
absFrameNum= absFrameNum+1; % Absolute frame number (to
correctly place info in cell array 'valuecell')
% process image, crop and save
currfrms=dat(ii).frms{jj}; % variable for the current frames to
analyze
fullsequence=squeeze(datasetJoined(:,:,:));
test_488=sum(fullsequence(:,:,currfrms),[],3); % do a sum
projection of all frames
test_488=squeeze(test_488);
fullsequence=squeeze(datasetJoined(:,:,:));
test_561=sum(fullsequence(:,:,currfrms),[],3); % do a sum
projection of all frames
test_561=squeeze(test_561);
fullsequence=squeeze(datasetJoined(:,:,:));
test_642=sum(fullsequence(:,:,currfrms),[],3); % do a sum
projection of all frames
test_642=squeeze(test_642);
svfilename=[dat(ii).filename '_' mat2str(currfrms(1)-1) '-'
mat2str(currfrms(size(currfrms,2)))]; % create filestring with filename
and frame range
dipsetpref('DefaultFigureWidth', 512,'DefaultFigureHeight',
512); % set default width of window to 512 to display next image
properly
h_raw=dipshow(test_642); % use to show the image
%
saveas(h_raw,fullfile(savedirFigs,[svfilename
'_raw.png']),'png')
saveas(h_raw,fullfile(savedirFigs,[svfilename
'_raw.fig']),'fig')
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% create sequence of 5 frames- just repeated image so that SPT
code can be
% used for fitting
sequence=repmat(test_488(256:end,0:255),[1 1 5]);
save(fullfile(savedir,[svfilename '_488.mat']),'sequence'); %
save 488 of image
sequence=repmat(test_561(0:255,0:255),[1 1 5]);
save(fullfile(savedir,[svfilename '_561.mat']),'sequence'); %
save 561 of image
sequence=repmat(test_642(0:255,256:511),[1 1 5]);
save(fullfile(savedir,[svfilename '_642.mat']),'sequence'); %
save 642 of image

%use spt to find positions of 488 channel
params=load(paramsfile);
sptObj488=SPT;
sptObj488.DataFile=fullfile(savedir,[svfilename '_488.mat'])
sptObj488.setParams(params);
sptObj488.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
488;
%
sptObj488.ParamsFindBoxCenters.maxPixelRegionSize=1; % change
sptObj488.findBoxCenters
% To prevent error if there are no spots in the image
if size(sptObj488.BoxCenters,1) == 0
TrackXY488 = [];
else
%
%

sptObj488.ParamsFilterFits.MinPhotons=.0001;
sptObj488.ParamsFilterFits.MinPValue= minPValue_488;
sptObj488.filterFits;

%to view overlay of fits and raw data (note that fits are
shifted already)
%
sptObj488.plotFitResults %plot results to compare
%
sptObj488.SaveBaseName=fullfile(savedir,[svfilename
%
'_488.mat']); --don't actually need this
sptObj488.saveFile(0);
% create gaussian blob series of 488 data (no shifting)
TrackXY488=[sptObj488.FitResults(1).xCoord(:,1)
sptObj488.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix
end
clear blnktot
blnk=dip_image(zeros(256,256));
if size(TrackXY488,1) == 1 % if statement added to avoid
creating a 2D instead of a 3D dip image when there are no spots
blnktot= dip_image(zeros(256,256,2));
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blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(TrackXY488,1)));
end
for kk=1:size(TrackXY488,1)
blnktot(:,:,kk1)=gaussianblob(blnk,TrackXY488(kk,:),1,5000,'spatial',3);
end
tots488=sum(blnktot,[],3);

%use SPT to find positions of 561 channel
params=load(paramsfile);
sptObj561=SPT;
sptObj561.DataFile=fullfile(savedir,[svfilename '_561.mat'])
sptObj561.setParams(params);
sptObj561.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
561; %have intensity value proportional to # of frames summed
%
sptObj561.ParamsFindBoxCenters.maxPixelRegionSize=1; % change
sptObj561.findBoxCenters
% To prevent error if there are no spots in the image (below is
% more code to prevent same error)
if size(sptObj561.BoxCenters,1) == 0
ShiftedTrackXY561 = [];
TrackXY561 = [];
else
sptObj561.ParamsFilterFits.MinPhotons=.0001;
sptObj561.ParamsFilterFits.MinPValue= minPValue_561;
sptObj561.filterFits;
%
sptObj561.plotFitResults %plot results to compare
%
sptObj561.SaveBaseName=fullfile(savedir,[svfilename
'_561.mat']); --don't actually need this
sptObj561.saveFile(0); % save .spt files
%

% Shift tracks from 561 channel
TrackXY561=[sptObj561.FitResults(1).xCoord(:,1)
sptObj561.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix
% Adding SXS pixels shifts channel 2 x-coordinates from
relative coordinates
% with channel 2 in isolation back to the absolute coordinates
used to
% construct the map with the channels side-by-side. The
mapping then
% transforms channel 2 into the coordinate space of channel 1.
[ ShiftedTrackXY561 ] = M561([TrackXY561(:, 1) + SXS,
TrackXY561(:, 2)]);
save(fullfile(savedir,[svfilename '_561shiftedvals.mat']),
'ShiftedTrackXY561'); %save shifted values
end
% create gaussian blob series of shifted data
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% Code modified to prevent error when 1 spot
clear blnktot
blnk=dip_image(zeros(256,256));
if size(ShiftedTrackXY561,1) == 1 % if statement added to
avoid creating a 2D instead of a 3D dip image when there are no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY561,1)));
end
for kk=1:size(ShiftedTrackXY561,1)
blnktot(:,:,kk1)=gaussianblob(blnk,ShiftedTrackXY561(kk,:),1,5000,'spatial',3);
end
tots561=sum(blnktot,[],3);
%
joinchannels('rgb',c(0:255,:),squeeze(tots561)*10) %-uncomment

%use SPT to find positions of 642 channel
params=load(paramsfile);
sptObj642=SPT;
sptObj642.DataFile=fullfile(savedir,[svfilename '_642.mat'])
sptObj642.setParams(params);
sptObj642.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
642; %have intensity value proportional to # of frames summed
%
sptObj642.ParamsFindBoxCenters.maxPixelRegionSize=1; % change
sptObj642.findBoxCenters
% To prevent error if there are no spots in the image (below is
% more code to prevent same error)
if size(sptObj642.BoxCenters,1) == 0
ShiftedTrackXY642 = [];
TrackXY642 = [];
else
sptObj642.ParamsFilterFits.MinPhotons=.0001;
sptObj642.ParamsFilterFits.MinPValue= minPValue_642;
sptObj642.filterFits;
%
sptObj642.plotFitResults %plot results to compare
%
sptObj642.SaveBaseName=fullfile(savedir,[svfilename
'_642.mat']); --don't actually need this
sptObj642.saveFile(0); % save .spt files
%

% Shift tracks from 642 channel
TrackXY642=[sptObj642.FitResults(1).xCoord(:,1)
sptObj642.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix
% Adding SXS pixels shifts channel 2 x-coordinates from
relative coordinates
% with channel 2 in isolation back to the absolute coordinates
used to
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% construct the map with the channels side-by-side. The
mapping then
% transforms channel 2 into the coordinate space of channel 1.
[ ShiftedTrackXY642 ] = M642([TrackXY642(:, 1) + SXS,
TrackXY642(:, 2)]);
save(fullfile(savedir,[svfilename '_642shiftedvals.mat']),
'ShiftedTrackXY642'); %save shifted values
end
% create gaussian blob series of shifted data
% Code modified to prevent error when 1 spot
clear blnktot
blnk=dip_image(zeros(256,256));
if size(ShiftedTrackXY642,1) == 1 % if statement added to
avoid creating a 2D instead of a 3D dip image when there are no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1)));
end
for kk=1:size(ShiftedTrackXY642,1)
blnktot(:,:,kk1)=gaussianblob(blnk,ShiftedTrackXY642(kk,:),1,5000,'spatial',3);
end
tots642=sum(blnktot,[],3);
%
joinchannels('rgb',c(0:255,:),squeeze(tots642)*10) %-uncomment

% To prevent error if there are no spots in any of the channels
% when trying to overlay shifted blobs
if size(TrackXY488,1)==0
tots488= dip_image(zeros(256,256,2));
tots488= tots488(:,:,1);
end

if size(ShiftedTrackXY561,1)==0
tots561= dip_image(zeros(256,256,2));
tots561= tots561(:,:,1);
end

if size(ShiftedTrackXY642,1)==0
tots642= dip_image(zeros(256,256,2)); % if statement added
to avoid creating a 2D instead of a 3D dip image when there are no
spots
tots642= tots642(:,:,1);
end
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% overlay shifted blobs on raw data
ovlayimage=joinchannels('rgb',tots642,tots488,tots561);
h_raw=dipshow(ovlayimage); % use to show the image
% save shifted images
saveas(h_raw,fullfile(savedirFigs,[svfilename
'_overlayedchannels.fig']),'fig')
saveas(h_raw,fullfile(savedirFigs,[svfilename
'_overlayedchannels.png']),'png')
%
close(h)% close image after saving

% Calculate number of spots in 561 channel overlapping with
spots in 488 channel
clear blnktot
if size(ShiftedTrackXY561,1) <= 1 % "if" statement added to
avoid creating a 2D instead of a 3D dip image when there are only 1 or
no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY561,1)));
end
numoverlap561w488 = 0; % number of overlapping blobs
pixallow = 1.0; % number of pixels allowed to be shifted
between overlapping blobs to consider them as being the same molecule
for mm=1:size(ShiftedTrackXY561,1)
for nn=1:size(TrackXY488,1)
if abs(ShiftedTrackXY561(mm,:)-TrackXY488(nn,:)) <
pixallow
numoverlap561w488 = numoverlap561w488+1;
blnktot(:,:,mm1)=gaussianblob(blnk,ShiftedTrackXY561(mm,:),1,5000,'spatial',3);
end
end
end
tots561ov488=sum(blnktot,[],3); % image with total overlapping
blobs in left channel

% Calculate number of spots in 642 channel overlapping with
spots in 488 channel
clear blnktot
if size(ShiftedTrackXY642,1) <= 1 % "if" statement added to
avoid creating a 2D instead of a 3D dip image when there are only 1 or
no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
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else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1)));
end
numoverlap642w488 = 0; % number of overlapping blobs
pixallow = 1.0; % number of pixels allowed to be shifted
between overlapping blobs to consider them as being the same molecule
for mm=1:size(ShiftedTrackXY642,1)
for nn=1:size(TrackXY488,1)
if abs(ShiftedTrackXY642(mm,:)-TrackXY488(nn,:)) <
pixallow
numoverlap642w488 = numoverlap642w488+1;
blnktot(:,:,mm1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3);
end
end
end
tots642ov488=sum(blnktot,[],3); % image with total overlapping
blobs in left channel

% Calculate number of spots in 642 channel overlapping with
spots in 561 channel
clear blnktot
if size(ShiftedTrackXY642,1) <= 1 % "if" statement added to
avoid creating a 2D instead of a 3D dip image when there are only 1 or
no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1)));
end
numoverlap642w561 = 0; % number of overlapping blobs
pixallow = 1.0; % number of pixels allowed to be shifted
between overlapping blobs to consider them as being the same molecule
for mm=1:size(ShiftedTrackXY642,1)
for nn=1:size(ShiftedTrackXY561,1)
if abs(ShiftedTrackXY642(mm,:)-ShiftedTrackXY561(nn,:))
< pixallow
numoverlap642w561 = numoverlap642w561+1;
blnktot(:,:,mm1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3);
end
end
end
tots642ov561=sum(blnktot,[],3); % image with total overlapping
blobs in left channel
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% Calculate number of spots overlapping in the three channels
(488, 561 and 642)
clear blnktot
if size(ShiftedTrackXY642,1) <= 1 % "if" statement added to
avoid creating a 2D instead of a 3D dip image when there are only 1 or
no spots
blnktot= dip_image(zeros(256,256,2));
blnktot= blnktot(:,:,1);
else
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1)));
end
numTripleOverlap = 0; % number of overlapping blobs
coordTripleOv = zeros(size(TrackXY488,1),2); % empty array to
place coordinates of 488 with triple overlap
pixallow = 1.0; % number of pixels allowed to be shifted
between overlapping blobs to consider them as being the same molecule
for mm=1:size(ShiftedTrackXY642,1)
for nn=1:size(ShiftedTrackXY561,1)
if abs(ShiftedTrackXY642(mm,:)-ShiftedTrackXY561(nn,:))
< pixallow
% If 642 spot overlaps with 561, then loop through
the
% 488 spots to check if it also overlaps with 488
spot
for nnTriple=1:size(TrackXY488,1)
if abs(ShiftedTrackXY642(mm,:)TrackXY488(nnTriple,:)) < pixallow
numTripleOverlap = numTripleOverlap+1;
coordTripleOv(numTripleOverlap,:)=
TrackXY488(nnTriple,:); % store number of tracks in 488 channel that
have triple overlap
blnktot(:,:,mm1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3);
end
end
end
end
end
totsTripleOverlap=sum(blnktot,[],3); % image with total
overlapping blobs in left channel
% Remove rows with all zeros and save coordinates
coordTripleOv(all(coordTripleOv==0,2),:)=[];
save(fullfile(savedir,[svfilename
'_488_tripleOverlapCoord.mat']), 'coordTripleOv');

% Display image with only of those spots overlapping with the
ones
% in 488 channel
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if isempty(tots642ov488)==0 || isempty(tots561ov488)==0
ovlayOnly=joinchannels('rgb',tots642ov488,tots488,tots561ov488); %
shows all green blobs and only those red (642) and blue (561) blobs
that overlay
h_ovlayOnly=dipshow(ovlayOnly); % use to show the image
saveas(h_ovlayOnly,fullfile(savedirFigs,[svfilename
'_overlayW488only.png']),'png')
else
end
%
% Display image with only of those 642 spots overlapping with
the ones
%
% in 561 channel
%
if isempty(tots642ov561)==0
%
ovlayOnly=joinchannels('rgb',tots642ov561,tots488,tots561); %
shows all green blobs and only those red blobs that overlay
%
h_ovlayOnly=dipshow(ovlayOnly); % use to show the image
%
saveas(h_ovlayOnly,fullfile(savedirFigs,[svfilename
'_overlaySpotsOnly.png']),'png')
%
else
%
end

% For reference below are the current column identifiers for
the
% cell array or spread sheet
%
colIdent= {'FileName', '488-fits','561-fits','642-fits',...
%
'488-561-overlaps','488-642-overlaps','561-642overlaps','Triple-overlap',...
%
'% 488 w/561','Average %','% 488 w/642','Average %','% 488
w/561-642','Average %',...
%
'% 488-561 w/642','Average %','% 488-642 w/561','Average %'};
% Concatenate results to cell array (see column identifiers
above)
% Add 1 (+1) to absFrameNum to count for column identifiers
valuecell(absFrameNum+1,:)={svfilename,size(TrackXY488,1),size(TrackXY5
61,1),size(TrackXY642,1)...
,numoverlap561w488,numoverlap642w488,numoverlap642w561,numTripleOverlap
,...
numoverlap561w488/size(TrackXY488,1)*100,'',numoverlap642w488/size(Trac
kXY488,1)*100,'',numTripleOverlap/size(TrackXY488,1)*100,'',...
numTripleOverlap/numoverlap561w488*100,'',numTripleOverlap/numoverlap64
2w488*100,''};
% Create overlayed localizations and raw data
locMask= newim(512,512); % Create figure to save mask with
localizations
locMask(256:end,0:255)= squeeze(tots488>600); % Add mask to
corresponding areas/channel
locMask(0:255,0:255)= squeeze(tots561>600);
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locMask(0:255,256:511)= squeeze(tots642>600);
h_rawOverlay=dipshow(overlay(test_642,locMask,[15000,0,0])); %
use to show the image
saveas(h_rawOverlay,fullfile(savedirFigs,[svfilename
'_rawOverlayLoc.fig']),'fig')

end
close all
end

%after loop write to excel and matlab files
xlswrite([filedir '\results.xls'],valuecell) % data saved in excel file
save([filedir '\results.mat'],'valuecell','coordTripleOv') % data saved
in matlab file
cd scripts % change current directory back to scripts folder
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APPENDIX B: BNGL files of rule-based models

BNGL file for model in Chapter 4
begin model

# References
# 1. Hause et al., 2012. Plos ONE.
# 2. Engelmann BW et al., 2014. Mol Cell Proteomics.
# 3. Kulak NA et al. (2014) Nat Methods 11: 319-324.
# 4. Shankaran H. et al., 2012. Molecular BioSystems.
# for plasma membrane the ref. is Hendriks 2003 (Cancer Research) and for
endosomes (pH 6.0) from French 1995
# 5. Kholodenko B.N. et al., 1999. The Journal of Biological Chemistry
# 6. Blinov M.L. et al., 2006. BioSystems
# 7. Chook, Yuh Min, et al. "The Grb2-mSos1 complex binds phosphopeptides with
higher affinity than
#
Grb2." Journal of Biological Chemistry 271.48 (1996): 30472-30478.
# 8. Macdonald JL, Pike LJ (2008) Proc Natl Acad Sci USA 105: 112-117.
# 9. Macdonald-Obermann JL, Pike LJ (2009) J Biol Chem 284: 13570-13576.
# 10. Elleman TC et al. (2001) Biochemistry 40: 8930-8939.
# 11. Low-Nam ST et al. (2011) Nat Struct Mol Biol 18: 1244-1249.
# 12. Kleiman LB et al. (2011) Mol Cell 43: 723Ð737.
# 13. Kim Y et al. (2012) Biochemistry 51 (25). American Chemical Society:
5212–22.
# 14. Morimatsu, Miki, et al. "Multiple-state reactions between the epidermal
growth factor
#
receptor and Grb2 as observed by using single-molecule analysis."
Proceedings of the National
#
Academy of Sciences 104.46 (2007): 18013-18018.
# 15. Reddy, Raven J., et al. "Early signaling dynamics of the epidermal
growth
#
factor receptor." Proceedings of the National Academy of Sciences 113.11
(2016): 3114-3119.

begin parameters
GRB2_total__FREE__ 3.50998295e+04 # Vary between 1e4 and 1e6 copies per cell
SHC1_total__FREE__ 4.72130741e+05 # Vary between 1e4 and 1e6 copies per cell
kdephos1068__FREE__ 1.83276225e+00 # Vary between 0.01 and 10
kphos1068__FREE__ 6.23793050e-01 # Vary between 0.01 and 10

# Keep constant
kon__ 5.0e6 # Assumed to be 5.0e6 /M/s
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kon_EGF__ 8.0e6 # This rate was set so EGFR phosphorylation kinetics occurs
similarly as observed by Reddy et. al (2016)
Kd_EGF__ 1.0e-9 # A typical value of 1 nM for the EGF dissociation constant
was used
ratio_kdephos__ 1.0 # Equal phosphoryaltion rates for pY1068 and pY1173 were
assumed
ratio_kphos__ 1.0 # Equal dephosphoryaltion rates for pY1068 and pY1173 were
assumed

# Avogadro constant
NA 6.02214e23 # [=] molecules per mol
# Fraction of cell to consider in a stochastic simulation
f 1 # [=] dimensionless, 0<=f<=1

# Cytoplasmic volume
#
A volume of 1 to 2 pL is typical for a mammalian cell.
Vc f*1.0e-12 # [=] L (1.0 pL)
# Number of cells per dish
numCells 1.0e7 # [=] cells per 60 mm^2 dish (10 million)
# Volume of media per dish
volMedia 1.0e-2 # [=] L (10 mL)
# Volume of extracellular fluid surrounding a cell
Vextra=f*volMedia/numCells

GRB2_total
GRB2_total__FREE__*f # [=] molecules per cell
EGFR_total 6.0e5*f # [=] molecules per cell (as estimated by flow cytometry
for this CHO EGFR-GFP cells)
SHC1_total
SHC1_total__FREE__*f # [=] molecules per cell

# Concentration of EGF
EGFconc 0 # [=] M
# EGFconc 25.0e-9 # [=] M
EGF_total=EGFconc*(NA*Vextra) # [=] molecules per cell

# A typical association rate constant for a protein-protein interaction
# A value of 1e7/M/s instead of 1e6/M/s (used originally) is closer to the on
rate estimated in Ref. 14 , which is ~1e7-1e8/M/s
# This value also allows off rates to be more similar to those estimated in
Ref. 14.
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kon kon__ # [=] /M/s
kon_EGF kon_EGF__ # [=] /M/s
# Dissocation and association rate constants for EGF-EGFR interaction at the
plasma membrane
Kd_EGF Kd_EGF__*(NA*Vextra) # [=] molecules . 1.0e-9nM
kp_EGF=kon_EGF/(NA*Vextra)
km_EGF=Kd_EGF*kp_EGF

# Dissociation constant for EGFR dimerization
#
This parameter is set so that EGFR_total/KD_dim >> 1 when number of
receptors is high (e.g. 6.0e5)
KD_dim 6.0e5/10 # [=] molecules per cell

# Dissocation and association rate constants for interaction between two
liganded (EGF-bound) receptors
# '_pre' because off rates will be modified by a factor of 'offrate_f'. If
offrate_f=1 then
# 'km_dim_L_L_pre' and 'km_dim_L_L' are the same.
km_dim_L_L_pre 0.273 # [=] /s (Ref 11)
kp_dim_L_L=km_dim_L_L_pre/KD_dim # [=] /(molecule/cell)/s

# Increase off rates by a factor of 'offrate_f'
offrate_f 1.0
km_dim_L_L=km_dim_L_L_pre*offrate_f

# Kd for Grb2-SH2 domain binding to pY1068 EGFR
Kd_GE 0.6e-6*(NA*Vc) # [=] molecules
, as estimated by Morimatsu et al.
(2007)
kp_GE=kon/(NA*Vc)
km_GE=Kd_GE*kp_GE

# Kd for SHC1-PTB domain binding to pY1173 EGFR
Kd_SE 0.6e-6*(NA*Vc) # [=] molecules , assumed to have equal Kd as Grb2
kp_SE=kon/(NA*Vc)
km_SE=Kd_SE*kp_SE

# Generic (pseudo first-order) dephosphorylation rate constant
#
From Ref. 12 we have that dephosphorylation rate of pY-EGFR on cells
after using gefitinib is
#
0.05/s, which corresponds to a half-life of 15 s and represents a lower
#
bound (estimation without considering protection of sites by binding
proteins and other influencing factors)
#
When considering Shc binding in the paper they come with a model (M3) with
1/sec rate for dephosphorylation (and
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#
2/sec for phosphorylation), which is the same dephos rate I had picked to
fit our data.
#
Note: keep in mind that they are using 10uM of gefitinib and according to
Ref. 13 that concentration would only
# inhibit 20-40% of the in vitro kinase activity of EGFR at Y1068, Y1148 and
Y1173.
kdephos1068 kdephos1068__FREE__ # 0.15
ratio_kdephos 1.0
kdephos1173 kdephos1068*ratio_kdephos
# Generic (pseudo first-order) phosphorylation rate constant
#
Value was set to fit experimental behavior observed by SiMPull
kphos1068 kphos1068__FREE__ # 0.043
ratio_kphos 1.0
kphos1173 kphos1068*ratio_kphos

end parameters
begin molecule types
# Ligand, growth factor
EGF(EGFL)
# Receptor tyrosine kinase, Epidermal growth factor receptor
#
I_III: domains I and III in the ectodomain for EGF binding
#
II: domain II for dimerization through ectodomain. Dimerization reaction
will change state of receptor
#
from monomer (unbound) to dimer (bound), and dissociation reaction the
opposite.
EGFR(I_III,II~u~b,Y1068~0~P,Y1173~0~P)
# Grb2 adaptor protein. SH3 represents both N- and C-terminus SH3 domains
GRB2(SH2)
#
SHC-Y317 in the p52 isoform | Y427 in the p66 isoform
SHC1(PTB)
end molecule types

begin seed species
EGF(EGFL) EGF_total
EGFR(I_III,II~u,Y1068~0,Y1173~0) EGFR_total
GRB2(SH2) GRB2_total
SHC1(PTB) SHC1_total

end seed species
begin observables
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Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules

EGF EGF()
EGFRtot EGFR()
Grb2tot GRB2()
Shc1tot SHC1()
EGFR_EGF EGFR(I_III!+)
monR EGFR(II~u)
dimR EGFR(II~b)
pY1068 EGFR(Y1068~P!?)
pY1173 EGFR(Y1173~P!?)
Grb2_EGFR GRB2(SH2!+)
Shc1_EGFR SHC1(PTB!+)

Molecules pY1068_pY1173 EGFR(Y1068~P!?,Y1173~P!?)
Molecules monR_pYpY EGFR(II~u,Y1068~P!?,Y1173~P!?)
Molecules dimR_pYpY EGFR(II~b,Y1068~P!?,Y1173~P!?)

end observables

begin functions
pY1068_percent() 100*pY1068/EGFRtot
pY1173_percent() 100*pY1173/EGFRtot
pYpY_per() 100*pY1068_pY1173/EGFRtot
random_pYpY_per() 100*(pY1068/EGFRtot)*(pY1173/EGFRtot)
monR_pYpY_per() 100*monR_pYpY/(monR+1) # +1 to avoid dividing by 0
dimR_pYpY_per() 100*dimR_pYpY/(dimR+1) # +1 to avoid dividing by 0

end functions

begin reaction rules
# EGF reversibly binds EGFR
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF

# Dimerization of EGFR for:
# Two EGF-bound receptors. Transition from monomer (II~u) to dimer (II~b)
states.
# Simplification: dimerization only happens between two EGF-bound receptors
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)->EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b)
kp_dim_L_L

# Dissociation of EGFR dimer.
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# Simplification: dimer dissociation occurs equally regardless of how many
receptors are EGF-bound (remember EGF can dissociate while in a dimer)
EGFR(II~b)->EGFR(II~u) km_dim_L_L

# EGFR autophosphorylation
#
Occurs only within a dimer
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068
EGFR(II~b,Y1173~0)->EGFR(II~b,Y1173~P) kphos1173
# Unregulated dephosphorylation of pTyr sites
#
(mediated by constitutively active phosphatases)
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068
EGFR(Y1173~P)->EGFR(Y1173~0) kdephos1173

# Binding of Grb2 to pY1068 in EGFR
GRB2(SH2)+EGFR(Y1068~P)<-> GRB2(SH2!1).EGFR(Y1068~P!1) kp_GE,km_GE

# Binding of SHC1 to pY1173 in EGFR
SHC1(PTB)+EGFR(Y1173~P)<-> SHC1(PTB!1).EGFR(Y1173~P!1) kp_SE,km_SE

end reaction rules
end model
begin actions
generate_network({overwrite=>1})
# Save parameters and concentrations before parameter scan
#saveParameters()
#saveConcentrations("pre_scan")
# Perform a parameter scan for EGF ligand concentrations
#parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05
e-9,0.1e-9,0.5e-9,1.0e-9,2.5e-9,5.0e-9,10.0e-9,50.0e-9],\
#
method=>"ode",t_start=>0,t_end=>600,n_steps=>600,print_functions=>1})
parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05e
-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1})

# Reset parameters and concentrations to those before parameter scan
#resetParameters()
#resetConcentrations("pre_scan")
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# Equilibrate for 300 seconds
#simulate({suffix=>"equil",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,pr
int_functions=>1})

# Add 25 nM EGF, and simulate for 300 seconds
setParameter("EGFconc","25.0e-9")
setConcentration("EGF(EGFL)","EGF_total")
simulate({suffix=>"EGF_25nM",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,
print_functions=>1})
end actions
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BNGL file for model in Chapter 5

begin model

# References
# 1. Hause et al., 2012. Plos ONE.
# 2. Engelmann BW et al., 2014. Mol Cell Proteomics.
# 3. Kulak NA et al. (2014) Nat Methods 11: 319-324.
# 4. Shankaran H. et al., 2012. Molecular BioSystems.
# for plasma membrane the ref. is Hendriks 2003 (Cancer Research) and for
endosomes (pH 6.0) from French 1995
# 5. Kholodenko B.N. et al., 1999. The Journal of Biological Chemistry
# 6. Blinov M.L. et al., 2006. BioSystems
# 7. Chook, Yuh Min, et al. "The Grb2-mSos1 complex binds phosphopeptides with
higher affinity than
#
Grb2." Journal of Biological Chemistry 271.48 (1996): 30472-30478.
# 8. Macdonald JL, Pike LJ (2008) Proc Natl Acad Sci USA 105: 112-117.
# 9. Macdonald-Obermann JL, Pike LJ (2009) J Biol Chem 284: 13570-13576.
# 10. Elleman TC et al. (2001) Biochemistry 40: 8930-8939.
# 11. Low-Nam ST et al. (2011) Nat Struct Mol Biol 18: 1244-1249.
# 12. Kleiman LB et al. (2011) Mol Cell 43: 723Ð737.
# 13. Kim Y et al. (2012) Biochemistry 51 (25). American Chemical Society:
5212–22.
# 14. Morimatsu M et al. (2007) PNAS 104 (46): 18013–18.
# 15. Tujin Shi, Mario Niepel,.., Peter K. Sorger, Wei-Jun Qian, H. Steven
Wiley.
#
Conservation of Protein Abundance Patterns Reveals the Regulatory
Architecture of the EGFR-MAPK Pathway.
#
Work in preparation to be submitted to Science Signaling.
# 16. Sun Q et al. (2010) PloS one 5, no. 9 (2010): e12819
# 17. Reddy, Raven J., et al. "Early signaling dynamics of the epidermal
growth
#
factor receptor." Proceedings of the National Academy of Sciences 113.11
(2016): 3114-3119.
begin parameters

alpha_Ub__FREE__ 1 # Vary between 20 and 100 for low Ub, or 1 and 4 for high
Ub
alpha_pY1045__FREE__ 1 # Vary between 1 and 100
kub__FREE__ 5.25555397e-02 # Vary between 0.001 and 0.1
kdeub__FREE__ 1.71408252e-02 # Vary between 0.001 and 0.1
Kd_CE__FREE__ 2.51475699e-07 # Vary between 0.1e-6 and 10.0e-6 M (0.1 uM to 10
uM)
Kd_CG__FREE__ 7.23610301e-07 # Vary between 0.1e-6 and 10.0e-6 M (0.1 uM to 10
uM)
kc__FREE__ 2.59365139e+08 # Vary between 5E5 5E8
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# Keep constant
alpha_CE__ 1 # Vary between 1 and 2
alpha_pYpY__ 1 # Vary between 1 and 100

CBL_total__ 5e3 # 5,000 copies per cell (from Capuani 2015)
kon__ 5.0e6 # Assumed to be 5.0e6 /M/s
kon_EGF__ 0.8e7 # # This rate was set so EGFR phosphorylation kinetics occurs
similarly as observed by Reddy et. al (2016)
Kd_EGF__ 1.0e-9 # A typical value of 1 nM for the EGF dissociation constant
was used
Kd_GE__ 0.6e-6 # 600 nM as estimated by Morimatsu et al. (2007)
kdephos1068__ 1.83276225e+00 # Estimated by fitting to SiMPull data
kphos1068__ 6.23793050e-01 # Estimated by fitting to SiMPull data
ratio_kdephos__ 1.0 # Equal phosphoryaltion rates for pY1045 and pY1068 were
assumed
ratio_kphos__ 1.0 # Equal phosphoryaltion rates for pY1045 and pY1068 were
assumed

# Scaling factors for BioNetFit
alpha_Ub alpha_Ub__FREE__
alpha_CE alpha_CE__
alpha_pY1045 alpha_pY1045__FREE__
alpha_pYpY alpha_pYpY__

# Avogadro constant
NA 6.02214e23 # [=] molecules per mol
# Fraction of cell to consider in a stochastic simulation
f 1 # [=] dimensionless, 0<=f<=1

# Cytoplasmic volume
#
A volume of 1 to 2 pL is typical for a mammalian cell.
Vc f*1.0e-12 # [=] L (1.0 pL)
# Number of cells per dish
numCells 1.0e7 # [=] cells per 60 mm^2 dish (10 million)
# Volume of media per dish
volMedia 1.0e-2 # [=] L (10 mL)
# Volume of extracellular fluid surrounding a cell
Vextra=f*volMedia/numCells

GRB2_total
1.0e6*f # [=] molecules per cell
EGFR_total 2.5e5*f # [=] molecules per cell (3e5 from Capuani 2015)
# Abundance of Cbl in several cell lines have been estimated to be 9,00015,000 copies/cell (Refs. 3 and 15)
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CBL_total
2015)

CBL_total__*f*1 # [=] molecules per cell. (5.2e3 from Capuani

# Concentration of EGF
EGFconc 0 # [=] M
# EGFconc 25.0e-9 # [=] M
EGF_total=EGFconc*(NA*Vextra) # [=] molecules per cell

# A typical association rate constant for a protein-protein interaction
# A value of 1e7/M/s instead of 1e6/M/s (used originally) is closer to the on
rate estimated in Ref. 14 , which is ~1e7-1e8/M/s
# This value also allows off rates to be more similar to those estimated in
Ref. 14.
kon kon__ # [=] /M/s
kon_EGF kon_EGF__ # [=] /M/s
# Dissocation and association rate constants for EGF-EGFR interaction at the
plasma membrane
Kd_EGF Kd_EGF__*(NA*Vextra) # [=] molecules . 1.0e-9nM
kp_EGF=kon_EGF/(NA*Vextra)
km_EGF=Kd_EGF*kp_EGF

# Dissociation constant for EGFR dimerization
#
This parameter is set so that EGFR_total/KD_dim >> 1 when number of
receptors is high (e.g. 6.0e5)
KD_dim 6.0e5/10 # [=] molecules per cell

# Dissocation and association rate constants for interaction between two
liganded (EGF-bound) receptors
# '_pre' because off rates will be modified by a factor of 'offrate_f'. If
offrate_f=1 then
# 'km_dim_L_L_pre' and 'km_dim_L_L' are the same.
km_dim_L_L_pre 0.273 # [=] /s (Ref 11)
kp_dim_L_L=km_dim_L_L_pre/KD_dim # [=] /(molecule/cell)/s

# Increase off rates by a factor of 'offrate_f'
offrate_f 1.0
km_dim_L_L=km_dim_L_L_pre*offrate_f

# Kd for Grb2-SH2 domain binding to pY1068 EGFR
Kd_GE Kd_GE__*(NA*Vc) # [=] molecules
, (2.6e-6*(NA*Vc)) from Ref. 1
kp_GE=kon/(NA*Vc)
km_GE=Kd_GE*kp_GE

118

# Kd for Cbl-TKB domain binding to pY1045 EGFR
Kd_CE=Kd_CE__FREE__*(NA*Vc) # [=] molecules , (1.0e-6*(NA*Vc)) from Ref. 16
kp_CE=kon/(NA*Vc)
km_CE=Kd_CE*kp_CE
# Kd for Cbl-PR region constitutive binding to the SH3 domains of Grb2
Kd_CG=Kd_CG__FREE__*(NA*Vc) # [=] molecules , from Ref. 16
kp_CG=kon/(NA*Vc)
km_CG=Kd_CG*kp_CG
# Cooperativity constant. In this case, association rates will be multiplied
by this constant to account for the
# increased local concentration, which in our context is the result of being
bound to the same molecular complex
kc kc__FREE__
# Association constants for reactions with cooperativity
# Grb2-SH2 domain binding to pY1068 or pY1086 EGFR when Grb2 is complexed with
a Cbl molecule bound to EGFR
kp_GE_c=kp_GE*kc
# Cbl-TKB domain binding to pY1045 EGFR when Cbl is complexed with a Grb2
molecule bound to EGFR (at pY1068 or pY1086)
kp_CE_c=kp_CE*kc
# Cbl-PR region binding to the SH3 domains of Grb2 when both molecules are
bound to the same receptor (Grb2 bound to pY1068 or pY1086)
kp_CG_c=kp_CG*kc

# Generic (pseudo first-order) dephosphorylation rate constant
#
From Ref. 12 we have that dephosphorylation rate of pY-EGFR on cells
after using gefitinib is
#
0.05/s, which corresponds to a half-life of 15 s and represents a lower
#
bound (estimation without considering protection of sites by binding
proteins and other influencing factors)
#
When considering Shc binding in the paper they come with a model (M3) with
1/sec rate for dephosphorylation (and
#
2/sec for phosphorylation), which is the same dephos rate I had picked to
fit our data.
#
Note: keep in mind that they are using 10uM of gefitinib and according to
Ref. 13 that concentration would only
# inhibit 20-40% of the in vitro kinase activity of EGFR at Y1068, Y1148 and
Y1173.
kdephos1068 kdephos1068__ # 0.15
ratio_kdephos ratio_kdephos__
kdephos1045 kdephos1068*ratio_kdephos
# Generic (pseudo first-order) phosphorylation rate constant
#
Value was set to fit experimental behavior observed by SiMPull
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kphos1068 kphos1068__ # 0.043
ratio_kphos ratio_kphos__
kphos1045 kphos1068*ratio_kphos

# Rate of ubiquitination and de-ubiquitination
kub kub__FREE__ # 0.03
kdeub kdeub__FREE__ # 0.01
maxValue 20 # Constant value to set max value of Y display in graph
end parameters
begin molecule types
# Ligand, growth factor
EGF(EGFL)
# Receptor tyrosine kinase, Epidermal growth factor receptor
#
I_III: domains I and III in the ectodomain for EGF binding
#
II: domain II for dimerization through ectodomain. Dimerization reaction
will change state of receptor
#
from monomer (unbound) to dimer (bound), and dissociation reaction the
opposite.
#
Lys_ub: Number of ubiquitin molecules covalently linked to lysines in
EGFR
EGFR(I_III,II~u~b,Y1045~0~P,Y1068~0~P,Lys_ub~0~1)
# Grb2 adaptor protein. SH3 represents both N- and C-terminus SH3 domains
GRB2(SH2,SH3)

# CBL E3 ubiquitin-protein ligase. Tyrosine-kinase binding motif (TKB)
contains a SH2-like domain near N-terminus.
# Poline-rich (PR) region closer to the C-terminus
CBL(TKB,PR)

end molecule types

begin seed species
EGF(EGFL) EGF_total
EGFR(I_III,II~u,Y1045~0,Y1068~0,Lys_ub~0) EGFR_total
GRB2(SH2,SH3) GRB2_total
CBL(TKB,PR) CBL_total

end seed species
begin observables
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Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules
Molecules

EGF EGF()
EGFRtot EGFR()
Grb2tot GRB2()
Cbltot CBL()
Cbl_EGFRpY1045 CBL(TKB!1).EGFR(Y1045~P!1)
Cbl_notEGFRpY1045 CBL(TKB)
EGFR_EGF EGFR(I_III!+)
monR EGFR(II~u)
dimR EGFR(II~b)
pY1045 EGFR(Y1045~P!?)
pY1068 EGFR(Y1068~P!?)
Grb2_EGFR GRB2(SH2!+)

Molecules Cbl_Grb2_comp CBL(PR!1).GRB2(SH3!1)
Molecules pY1045_pY1068 EGFR(Y1045~P!?,Y1068~P!?)
Molecules monR_pYpY EGFR(II~u,Y1045~P!?,Y1068~P!?)
Molecules dimR_pYpY EGFR(II~b,Y1045~P!?,Y1068~P!?)
Molecules EGFR_ub EGFR(Lys_ub~1)
#Molecules EGFRpY1068_Grb2_Cbl_loop
GRB2(SH2!3,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P!3)
#Molecules EGFRpY1068_Grb2_Cbl_open1
GRB2(SH2,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P)
#Molecules EGFRpY1068_Grb2_Cbl_open2
CBL(TKB,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P)
#Molecules EGFRpY1068_Grb2_Cbl_open3
CBL(PR,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3)

end observables

begin functions
pY1045_percent() 100*pY1045/EGFRtot
pY1068_percent() 100*pY1068/EGFRtot
pYpY_per() 100*pY1045_pY1068/EGFRtot
random_pYpY_per() 100*(pY1068/EGFRtot)*(pY1045/EGFRtot)
Cbl_EGFR_per() 100*Cbl_EGFRpY1045/Cbltot
monR_pYpY_per() 100*monR_pYpY/(monR+1) # +1 to avoid dividing by 0
dimR_pYpY_per() 100*dimR_pYpY/(dimR+1) # +1 to avoid dividing by 0
BNF_Cbl_EGFR_per() alpha_CE*100*Cbl_EGFRpY1045/Cbltot
BNF_pY1045_per() alpha_pY1045*100*pY1045/EGFRtot
BNF_pYpY_per() alpha_pYpY*100*pY1045_pY1068/EGFRtot

# Percent of receptors ubiquitinated
Ubiq_EGFR_per() 100*EGFR_ub/EGFRtot
BNF_Ub1_EGFR_per() alpha_Ub*100*EGFR_ub/EGFRtot # Ub1 is for WT
BNF_Ub2_EGFR_per() alpha_Ub*2.5*100*EGFR_ub/EGFRtot # Ub2 is for Y1045+ mutant
(no-cooperativity) (multiply by 2.5 because max should be 40)
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end functions

begin reaction rules
# EGF reversibly binds EGFR
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF

# Dimerization of EGFR for:
# Two EGF-bound receptors. Transition from monomer (II~u) to dimer (II~b)
states.
# Simplification: dimerization only happens between two EGF-bound receptors
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)->EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b)
kp_dim_L_L

# Dissociation of EGFR dimer.
# Simplification: dimer dissociation occurs equally regardless of how many
receptors are EGF-bound (remember EGF can dissociate while in a dimer)
EGFR(II~b)->EGFR(II~u) km_dim_L_L

# EGFR autophosphorylation
#
Occurs only within a dimer
EGFR(II~b,Y1045~0)->EGFR(II~b,Y1045~P) kphos1045
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068
# Unregulated dephosphorylation of pTyr sites
#
(mediated by constitutively active phosphatases)
EGFR(Y1045~P)->EGFR(Y1045~0) kdephos1045
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068

# Binding of Grb2 to pY1068 in EGFR when it is free in solution, either as
Grb2 or Cbl-Grb2 complex.
# In the model Grb2 cannot bind to both pY1068 and pY1086 simultaneously
# You need to specify each molecular complex specifically to avoid duplicate
rules
GRB2(SH2,SH3)+EGFR(Y1068~P)<-> GRB2(SH2!1,SH3).EGFR(Y1068~P!1) kp_GE,km_GE
GRB2(SH2,SH3!1).CBL(PR!1,TKB)+EGFR(Y1068~P)<->
GRB2(SH2!2,SH3!1).CBL(PR!1,TKB).EGFR(Y1068~P!2) kp_GE,km_GE

# Binding of CBL to pY1045 in EGFR when it is free in solution, either as Cbl
or Cbl-Grb2 complex
CBL(TKB,PR)+EGFR(Y1045~P) <-> CBL(TKB!1,PR).EGFR(Y1045~P!1) kp_CE,km_CE
CBL(TKB,PR!1).GRB2(SH2,SH3!1)+EGFR(Y1045~P) <->
CBL(TKB!2,PR!1).GRB2(SH2,SH3!1).EGFR(Y1045~P!2) kp_CE,km_CE
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# Constitutive association of CBL proline-rich region to the SH3 domains of
Grb2
# When both CBL and GRB2 are free in solution
CBL(TKB,PR)+GRB2(SH2,SH3) <-> CBL(TKB,PR!1).GRB2(SH2,SH3!1) kp_CG,km_CG
# When either one of them is bound to pYEGFR and the other one free in
solution
CBL(TKB!+,PR)+GRB2(SH2,SH3) <-> CBL(TKB!+,PR!1).GRB2(SH2,SH3!1) kp_CG,km_CG
CBL(TKB,PR)+GRB2(SH2!+,SH3) <-> CBL(TKB,PR!1).GRB2(SH2!+,SH3!1) kp_CG,km_CG

# Association reactions having cooperativity. The following reactions occur
between molecules bound
# to the same molecular complexes, this increases the local concentration of
the reactants and therefore
# the association rates
# Cooperative binding of Grb2 to pY1068 and pY1086 in EGFR
# In the model Grb2 cannot bind to both pY1068 and pY1086 simultaneously
GRB2(SH2,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P) <->
GRB2(SH2!3,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P!3) kp_GE_c,km_GE
# Cooperative binding of CBL to pY1045 in EGFR
CBL(TKB,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P) <->
CBL(TKB!3,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P!3) kp_CE_c,km_CE
# Cooperative binding of CBL proline-rich region to the SH3 domains of Grb2
when both molecules are bount to EGFR
CBL(PR,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3) <->
CBL(PR!3,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3!3) kp_CG_c,km_CG

# Ubiquitination of EGFR when Cbl is bound to the receptor (directly or
through Grb2 bound to pY1068 or pY1086)
# Direct binding
EGFR(Y1045~P!+,Lys_ub~0)->EGFR(Y1045~P!+,Lys_ub~1) kub
# Indirect binding (pY1045 should be free and CBL should have its TKB free)
EGFR(Y1045,Y1068~P!1,Lys_ub~0).GRB2(SH2!1,SH3!2).CBL(TKB,PR!2)>EGFR(Y1045,Y1068~P!1,Lys_ub~1).GRB2(SH2!1,SH3!2).CBL(TKB,PR!2) kub
# De-ubiquitination of EGFR
EGFR(Lys_ub~1)->EGFR(Lys_ub~0) kdeub

end reaction rules
end model
begin actions
generate_network({overwrite=>1})
# Save parameters and concentrations before parameter scan
#saveParameters()
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#saveConcentrations("pre_scan")

parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05e
-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1})
# Eliminate Grb2 binding and therefore cooperative recruitment of Cbl
setParameter("kp_GE",0.0);
parameter_scan({suffix=>"dose_resp_no_coop",parameter=>"EGFconc",par_scan_vals
=>[0.05e-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1})

# Reset parameters and concentrations to those before parameter scan
#resetParameters()
#resetConcentrations("pre_scan")
# Equilibrate for 300 seconds
#simulate({suffix=>"equil",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,pr
int_functions=>1})

## Add 25 nM EGF, and simulate for 300 seconds
#setParameter("EGFconc","25.0e-9")
#setConcentration("EGF(EGFL)","EGF_total")
#simulate({suffix=>"EGF_25nM",method=>"ode",t_start=>0,t_end=>30,n_steps=>50,p
rint_functions=>1})
end actions
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APPENDIX C: Configuration files for parameter estimation (.conf)

Configuration file for model in Chapter 4
#############
### PATHS ###
#############
# The directory to which job output will be written
output_dir=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/output/
# The BioNetGen executable
# bng_command=Simulators/BNG2.pl
bng_command=
/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/Simulators/BNG2.pl
# ESC added the following two lines because NFsim was not able to run
simulations
# NFsim for Cygwin
#nfsim_dir=/home/esc1987/Modeling/NFsim_v1.11/bin
#nfsim_command=NFsim_x86_64-cygwin
#nfsim_command=NFsim_i686-cygwin
# The model file to be used in fitting simulations
model=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/fit
_v1_16/180222_CHO_EGFR.bngl

# The experimental data to be fit
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_16/dose_resp.exp
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_16/EGF_25nM.exp
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#######################
### General Options ###
#######################
# The job name
job_name=fit_v1_16_2
# Whether or not to generate plots for best-fit outputs
make_plots=0
# Number of simulations to run in parallel.
# Change parellel_count to the number of CPU cores on your machine for
increased performance.
parallel_count=5
# Kill a job and continue without it if process runs longer than walltime. Adjust if
needed.
max_walltime=10:00
# Delete files that are no longer needed to save disk space
# Property not working
delete_old_files=1
# Ask if you want to overwrite existing existing job output. In this case disable
ask, that way you can do batch fitting

#######################
### Fitting Options ###
#######################
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# Which objective function to minimize in fitting. A complete list of objective
functions is described in GenFit documentation.
# 1: sum-of-squares function (i.e. nonlinear least squares fitting).
# 2 chi-square function (i.e. weighted nonlinear least squares fitting)
objfunc=1
# Do not divide by initial value (at t=0) of simulation results
divide_by_init= 0
# The maximum number of generations to run.
max_generations=75
# The number of unique parameter sets simulated in first generation.
first_gen_permutations=150
# The number of unique parameter sets simulated in a generation.
permutations=75
# Do bootstrapping
bootstrap= 100
bootstrap_chi= 30

# The mutation probability and mutation factor for free parameters.
mutate=default 0.2 0.2
# The free parameters. These are generated on a random log scale between
numbers indicated.
loguniform_var=GRB2_total__FREE__ 1E4 1E6
loguniform_var=SHC1_total__FREE__ 1E4 1E6
loguniform_var=kdephos1068__FREE__ 0.5 5
loguniform_var=kphos1068__FREE__ 0.5 5
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Configuration file for model in Chapter 5

#############
### PATHS ###
#############
# The directory to which job output will be written
output_dir=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/output/
# The BioNetGen executable
# bng_command=Simulators/BNG2.pl
bng_command=
/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/Simulators/BNG2.pl
# ESC added the following two lines because NFsim was not able to run
simulations
# NFsim for Cygwin
#nfsim_dir=/home/esc1987/Modeling/NFsim_v1.11/bin
#nfsim_command=NFsim_x86_64-cygwin
#nfsim_command=NFsim_i686-cygwin
# The model file to be used in fitting simulations
model=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/fit
_v1_17/180301_HeLa_EGFR_Cbl_Ub.bngl

# The experimental data to be fit
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_17/dose_resp.exp
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_17/dose_resp_no_coop.exp
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#######################
### General Options ###
#######################
# The job name
job_name=fit_v1_17
# Whether or not to generate plots for best-fit outputs
make_plots=0
# Number of simulations to run in parallel.
# Change parellel_count to the number of CPU cores on your machine for
increased performance.
parallel_count=6
# Kill a job and continue without it if process runs longer than walltime. Adjust if
needed.
max_walltime=10:00
# Delete files that are no longer needed to save disk space
# Property not working
delete_old_files=1
# Ask if you want to overwrite existing existing job output. In this case disable
ask, that way you can do batch fitting

#######################
### Fitting Options ###
#######################
# Which objective function to minimize in fitting. A complete list of objective
functions is described in GenFit documentation.
# 1: sum-of-squares function (i.e. nonlinear least squares fitting).
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# 2 chi-square function (i.e. weighted nonlinear least squares fitting)
objfunc=1
# The maximum number of generations to run.
max_generations=75
# The number of unique parameter sets simulated in first generation.
first_gen_permutations=150
# The number of unique parameter sets simulated in a generation.
permutations=75
# Do bootstrapping
bootstrap= 6
bootstrap_chi= 35
# Do not divide by initial value (at t=0) of simulation results
divide_by_init= 0

# The mutation probability and mutation factor for free parameters.
mutate=default 0.2 0.2

# The free parameters.
# These are scaling factors generated on a random scale between numbers
indicated.
#random_var=alpha_pY1045__FREE__ 4 20
#random_var=alpha_Ub__FREE__ 20 100
random_var=alpha_pY1045__FREE__ 1 100
random_var=alpha_Ub__FREE__ 6 60
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# These are generated on a random log scale between numbers indicated.
loguniform_var=Kd_CE__FREE__ 0.1E-6 10.0E-6
loguniform_var=Kd_CG__FREE__ 0.1E-6 10.0E-6
loguniform_var=kc__FREE__ 5E5 5E8
loguniform_var=kub__FREE__ 0.001 0.1
loguniform_var=kdeub__FREE__ 0.001 0.1
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